

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Advances in risk stratification of bladder cancer... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-1137/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-1137" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Advances in risk stratification of bladder cancer to guide personalized medicine" />
    
            <meta name="og:title" content="F1000Research Article: Advances in risk stratification of bladder cancer to guide personalized medicine.">
            <meta name="og:description" content="Read the latest article version by Justin T. Matulay, Ashish M. Kamat, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="16224">
            <meta name="article-id" content="14903">
            <meta name="dc.title" content="Advances in risk stratification of bladder cancer to guide personalized medicine">
            <meta name="dc.description" content="Bladder cancer is a heterogeneous disease that poses unique challenges to the treating clinician. It can be limited to a relatively indolent papillary tumor with low potential for progression beyond this stage to muscle-invasive disease prone to distant metastasis. The former is best treated as conservatively as possible, whereas the latter requires aggressive surgical intervention with adjuvant therapies in order to provide the best clinical outcomes. Risk stratification traditionally uses clinicopathologic features of the disease to provide prognostic information that assists in choosing the best therapy for each individual patient. For bladder cancer, this informs decisions regarding the type of intravesical therapy that is most appropriate for non-muscle-invasive disease or whether or not to administer neoadjuvant chemotherapy prior to radical cystectomy. More recently, tumor genetic sequencing data have been married to clinical outcomes data to add further sophistication and personalization. In the next generation of risk classification, we are likely to see the inclusion of molecular subtyping with specific treatment considerations based on a tumor&rsquo;s mutational profile.">
            <meta name="dc.subject" content="Bladder cancer, bladder cancer genetics, personalized medicine, risk stratification, urothelial carcinoma">
            <meta name="dc.creator" content="Matulay, Justin T.">
            <meta name="dc.creator" content="Kamat, Ashish M.">
            <meta name="dc.date" content="2018/07/25">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.14903.1">
            <meta name="dc.source" content="F1000Research 2018 7:1137">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Bladder cancer">
            <meta name="prism.keyword" content="bladder cancer genetics">
            <meta name="prism.keyword" content="personalized medicine">
            <meta name="prism.keyword" content="risk stratification">
            <meta name="prism.keyword" content="urothelial carcinoma">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/07/25">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="1137">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.14903.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-1137">
            <meta name="citation_title" content="Advances in risk stratification of bladder cancer to guide personalized medicine">
            <meta name="citation_abstract" content="Bladder cancer is a heterogeneous disease that poses unique challenges to the treating clinician. It can be limited to a relatively indolent papillary tumor with low potential for progression beyond this stage to muscle-invasive disease prone to distant metastasis. The former is best treated as conservatively as possible, whereas the latter requires aggressive surgical intervention with adjuvant therapies in order to provide the best clinical outcomes. Risk stratification traditionally uses clinicopathologic features of the disease to provide prognostic information that assists in choosing the best therapy for each individual patient. For bladder cancer, this informs decisions regarding the type of intravesical therapy that is most appropriate for non-muscle-invasive disease or whether or not to administer neoadjuvant chemotherapy prior to radical cystectomy. More recently, tumor genetic sequencing data have been married to clinical outcomes data to add further sophistication and personalization. In the next generation of risk classification, we are likely to see the inclusion of molecular subtyping with specific treatment considerations based on a tumor&rsquo;s mutational profile.">
            <meta name="citation_description" content="Bladder cancer is a heterogeneous disease that poses unique challenges to the treating clinician. It can be limited to a relatively indolent papillary tumor with low potential for progression beyond this stage to muscle-invasive disease prone to distant metastasis. The former is best treated as conservatively as possible, whereas the latter requires aggressive surgical intervention with adjuvant therapies in order to provide the best clinical outcomes. Risk stratification traditionally uses clinicopathologic features of the disease to provide prognostic information that assists in choosing the best therapy for each individual patient. For bladder cancer, this informs decisions regarding the type of intravesical therapy that is most appropriate for non-muscle-invasive disease or whether or not to administer neoadjuvant chemotherapy prior to radical cystectomy. More recently, tumor genetic sequencing data have been married to clinical outcomes data to add further sophistication and personalization. In the next generation of risk classification, we are likely to see the inclusion of molecular subtyping with specific treatment considerations based on a tumor&rsquo;s mutational profile.">
            <meta name="citation_keywords" content="Bladder cancer, bladder cancer genetics, personalized medicine, risk stratification, urothelial carcinoma">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Justin T. Matulay">
            <meta name="citation_author_institution" content="Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Suite 853, Houston, TX, 77030, USA">
            <meta name="citation_author" content="Ashish M. Kamat">
            <meta name="citation_author_institution" content="Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Suite 853, Houston, TX, 77030, USA">
            <meta name="citation_publication_date" content="2018/07/25">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="1137">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.14903.1">
            <meta name="citation_firstpage" content="1137">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-1137/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-1137.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=16224 /> <input type=hidden id=articleId name=articleId value=14903 /> <input type=hidden id=xmlUrl value="/articles/7-1137/v1/xml"/> <input type=hidden id=xmlFileName value="-7-1137-v1.xml"> <input type=hidden id=article_uuid value=f21eaa3f-9a22-415e-b3b6-84c7e4dff4fd /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Advances in risk stratification of bladder cancer to guide personalized medicine"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.14903.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.14903.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-1137"
  },
  "headline": "Advances in risk stratification of bladder cancer to guide personalized medicine",
  "datePublished": "2018-07-25T15:49:59",
  "dateModified": "2018-07-25T15:49:59",
  "author": [
    {
      "@type": "Person",
      "name": "Justin T. Matulay"
    },    {
      "@type": "Person",
      "name": "Ashish M. Kamat"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Bladder cancer is a heterogeneous disease that poses unique challenges to the treating clinician. It can be limited to a relatively indolent papillary tumor with low potential for progression beyond this stage to muscle-invasive disease prone to distant metastasis. The former is best treated as conservatively as possible, whereas the latter requires aggressive surgical intervention with adjuvant therapies in order to provide the best clinical outcomes. Risk stratification traditionally uses clinicopathologic features of the disease to provide prognostic information that assists in choosing the best therapy for each individual patient. For bladder cancer, this informs decisions regarding the type of intravesical therapy that is most appropriate for non-muscle-invasive disease or whether or not to administer neoadjuvant chemotherapy prior to radical cystectomy. More recently, tumor genetic sequencing data have been married to clinical outcomes data to add further sophistication and personalization. In the next generation of risk classification, we are likely to see the inclusion of molecular subtyping with specific treatment considerations based on a tumor&rsquo;s mutational profile."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-1137",
            "name": "Advances in risk stratification of bladder cancer to guide personalized..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Advances in risk stratification of bladder cancer to guide personalized... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=16224 data-id=14903 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14903.1" data-recommended="" data-doi="10.12688/f1000research.14903.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-1137/v1/pdf?article_uuid=f21eaa3f-9a22-415e-b3b6-84c7e4dff4fd" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-14903-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-14903-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-14903-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Matulay JT and Kamat AM. Advances in risk stratification of bladder cancer to guide personalized medicine [version 1; peer review: 4 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1137 (<a class=new-orange href="https://doi.org/10.12688/f1000research.14903.1" target=_blank>https://doi.org/10.12688/f1000research.14903.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-14903-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=14903 id=track-article-signin-14903 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14903?target=/articles/7-1137">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16224 /> <input name=articleId type=hidden value=14903 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Advances in risk stratification of bladder cancer to guide personalized medicine</h1><span class=other-info> [version 1; peer review: 4 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Justin T. Matulay<a href="https://orcid.org/0000-0002-2467-5710" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-2467-5710</div>,&nbsp;</span><span class=""><a href="mailto:akamat@mdanderson.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Ashish M. Kamat</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Justin T. Matulay<a href="http://orcid.org/0000-0002-2467-5710" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-2467-5710</div>,&nbsp;</span><span class=""><a href="mailto:akamat@mdanderson.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Ashish M. Kamat</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 25 Jul 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.14903.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Suite 853, Houston, TX, 77030, USA<br/> <p> <div class=margin-bottom> Justin T. Matulay <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Ashish M. Kamat <br/> <span>Roles: </span> Conceptualization, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=36731-36210></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=36733-36209></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=36734-36208></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=36732-36211></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Bladder cancer is a heterogeneous disease that poses unique challenges to the treating clinician. It can be limited to a relatively indolent papillary tumor with low potential for progression beyond this stage to muscle-invasive disease prone to distant metastasis. The former is best treated as conservatively as possible, whereas the latter requires aggressive surgical intervention with adjuvant therapies in order to provide the best clinical outcomes. Risk stratification traditionally uses clinicopathologic features of the disease to provide prognostic information that assists in choosing the best therapy for each individual patient. For bladder cancer, this informs decisions regarding the type of intravesical therapy that is most appropriate for non-muscle-invasive disease or whether or not to administer neoadjuvant chemotherapy prior to radical cystectomy. More recently, tumor genetic sequencing data have been married to clinical outcomes data to add further sophistication and personalization. In the next generation of risk classification, we are likely to see the inclusion of molecular subtyping with specific treatment considerations based on a tumor’s mutational profile. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Bladder cancer, bladder cancer genetics, personalized medicine, risk stratification, urothelial carcinoma </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Ashish M. Kamat (<a href="mailto:akamat@mdanderson.org">akamat@mdanderson.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Ashish M. Kamat </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> AMK is a consultant to TMC Innovation, Merck, BMS, Arquer, MDxHealth, Photocure, Theralase, Cepheid, Medac, Asieris, Pfizer, and Astra Zeneca and has received research funding from FKD, Merck, Telesta, and Adolo. JTM has no competing interests to declare. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> AMK is supported by the Wayne B. Duddlesten Professorship and a Floyd Family Foundation Grant. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Matulay JT and Kamat AM. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Matulay JT and Kamat AM. Advances in risk stratification of bladder cancer to guide personalized medicine [version 1; peer review: 4 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1137 (<a href="https://doi.org/10.12688/f1000research.14903.1" target=_blank>https://doi.org/10.12688/f1000research.14903.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 25 Jul 2018, <b>7</b>(F1000 Faculty Rev):1137 (<a href="https://doi.org/10.12688/f1000research.14903.1" target=_blank>https://doi.org/10.12688/f1000research.14903.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 25 Jul 2018, <b>7</b>(F1000 Faculty Rev):1137 (<a href="https://doi.org/10.12688/f1000research.14903.1" target=_blank>https://doi.org/10.12688/f1000research.14903.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d36661e159>Introduction</h2><p class="" id=d36661e162>Bladder cancer ranks among the most common non-cutaneous malignancies in the United States (4<sup>th</sup> for men and 11<sup>th</sup> for women) and worldwide (6<sup>th</sup> for men and 16<sup>th</sup> for women)<sup><a href="#ref-1">1</a>–<a href="#ref-3">3</a></sup>. Though it is commonly referred to by the generic term “bladder cancer”, urothelial neoplasms represent a broad spectrum of disease with vastly different treatment pathways from routine bladder surveillance to intravesical therapy to radical surgery with chemotherapy. Staging is broadly divided into two major categories—non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC)—which is perhaps the most important determining factor when choosing an initial therapy. Tumor stage is classified according to the Tumor-Node-Metastasis staging system developed by a collaboration of the American Joint Commission on Cancer and Union for International Cancer Control, now in its 8<sup>th</sup> edition which went into effect in January 2018<sup><a href="#ref-4">4</a></sup>. Tumors categorized as NMIBC include carcinoma <i>in situ</i> (CIS), papillary (Ta), or invasive into or beyond the lamina propria (T1). Once the tumor invades the muscularis propria (T2) or beyond (T3 and T4), it is considered MIBC. Somewhat confusingly, these have been referred to as “superficial” and “invasive” disease, respectively, though that practice has been abandoned more recently for the sake of clarity. The tumor grade, describing the aggressiveness of tumor cells based on microscopic appearance, is also very important for the prognosis of bladder cancer. The 2016 World Health Organization classification system for urothelial carcinoma is divided into a binary system of high and low grade, though this is mainly applicable to Ta tumors, since nearly all (≥95%) disease ≥T1 is high grade and CIS is high grade by definition<sup><a href="#ref-5">5</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36661e202>Diagnosis</h2><p class="" id=d36661e205>A complete clinical assessment for bladder cancer includes history, physical exam, imaging of the upper urinary tracts, and cystoscopy. Cystoscopy is the cornerstone in the diagnosis and treatment of bladder cancer, being used in virtually all patients at some point throughout the course of their disease. Traditionally, this is carried out using a standard light source (“white light”) to illuminate an endoscopic lens with the subsequent image transmitted via a camera head to a monitor. Directly visualized tumors are then biopsied, fulgurated, and/or resected to provide staging information that forms the basis for widely different treatments (i.e. surveillance versus radical cystectomy). Low-grade, papillary tumors not invading into the lamina propria (Ta) are reliably eradicated in a single setting; however, more advanced disease (high-grade and/or T1) is often incompletely resected. Studies have found residual disease to be present in 40–78% of re-transurethral resection (TUR) specimens after original diagnosis of high-grade Ta or any T1, with an upgrading rate to muscle invasion of 2% and 14%, respectively<sup><a href="#ref-6">6</a>–<a href="#ref-9">9</a></sup>. This fact has led to the recommendation by leading urologic organizations that all patients with T1 tumors should undergo a repeat resection within 6 weeks of the original procedure to confirm tumor stage and ensure maximal removal of any residual disease, as this improves response to intravesical therapy<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>. Recent technological advances, referred to as photodynamic aids (i.e. Blue Light® cystoscopy and narrow band imaging), promise improved detection over traditional white light cystoscopy alone, theoretically allowing for a more complete endoscopic tumor removal and more accurate risk assessment<sup><a href="#ref-12">12</a>–<a href="#ref-19">19</a></sup>.</p><p class="" id=d36661e229>The urothelium is not limited to the bladder and urethra; it also extends into the ureters and renal collecting system. The main purpose of imaging in the diagnostic evaluation of bladder cancer is to assess the upper urinary tracts for malignancy and for staging local and distant extent of disease. Computed tomographic urography, which uses intravenous contrast with delayed image acquisition (10–15 minutes) to allow for urinary excretion, has the highest diagnostic value for the detection of upper tract malignancy with a sensitivity of 67–100% and a specificity of 93–99%<sup><a href="#ref-20">20</a>–<a href="#ref-23">23</a></sup>. Magnetic resonance imaging is a viable alternative in patients with iodinated contrast allergy with a diagnostic accuracy of 84–92%, though it is more time intensive and still requires a contrast agent (gadolinium) and, therefore, is a poor choice in patients with significantly impaired renal function<sup><a href="#ref-24">24</a></sup>. Ultrasonography plus retrograde pyelography at the time of cystoscopy can be used if cross-sectional imaging is otherwise contraindicated, but this is suboptimal for assessing disease extent and upper tract involvement, so it is reserved for special circumstances. Upper tract evaluation is recommended as part of initial diagnostic work-up by the American Urological Association (AUA) and European Association of Urology (EAU) despite the very low likelihood of finding synchronous upper tract tumor at the time of NMIBC diagnosis (1.5%); however, certain features like multifocality, trigonal location, and CIS increase the risk (7.5%)<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a>,<a href="#ref-25">25</a>,<a href="#ref-26">26</a></sup>. A more nuanced approach to long-term surveillance is favored over repeat imaging, being applied only to patients with high-risk tumors, and is our first example of a risk-adapted approach to bladder cancer.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36661e259>Risk stratification in bladder cancer</h2><p class="" id=d36661e262>Not all bladder cancers are created equal and, therefore, risk stratification is an important tool for achieving optimal patient outcomes while avoiding overtreatment. Formal classification systems exist for NMIBC given the wide variability in possible treatment options (surveillance to radical cystectomy), but a one-size-fits-all approach to MIBC is no longer appropriate either.</p><div class=section><a name=d36661e265 class=n-a></a><h3 class=section-title>Non-muscle-invasive bladder cancer</h3><p class="" id=d36661e270>The risk tables from the European Organization for Research and Treatment of Cancer (EORTC) and scoring system from the Spanish Urological Club for Oncological Treatment (CUETO) for NMIBC classify patients into low, intermediate, or high risk for recurrence and progression to muscle invasion based on factors including grade, stage, tumor size, multifocality, variant histology, lymphovascular invasion, and prior therapy<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a>,<a href="#ref-27">27</a>,<a href="#ref-28">28</a></sup>. Validation studies based on these tools have shown consistent overestimation of recurrence and progression rates among the high-risk group, likely owing to the suboptimal administration of intravesical therapy seen in the developmental cohorts<sup><a href="#ref-29">29</a>–<a href="#ref-32">32</a></sup>. Though there is now widespread acceptance of induction intravesical immunotherapy (bacillus Calmette-Guérin [BCG]) plus maintenance therapy for 1 to 3 years based on the results of the randomized Southwest Oncology Group (SWOG) protocol, patients from EORTC and CUETO were largely treated with intravesical chemotherapies (mitomycin C, epirubicin, thiotepa, etc.) or a lack of appropriate maintenance BCG<sup><a href="#ref-33">33</a></sup>. Despite the limitations of both aforementioned studies, they form the foundation for the risk stratification systems used by the EAU and AUA to help guide treatment decisions (<a href="#T1">Table 1</a>)<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a>,<a href="#ref-34">34</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Risk stratification of non-muscle-invasive bladder cancer<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d36661e328 class=n-a></a><thead><a name=d36661e330 class=n-a></a><tr><a name=d36661e332 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d36661e334 class=n-a></a>Risk category</th><th align=left colspan=1 rowspan=1 valign=top><a name=d36661e337 class=n-a></a>EAU definition<sup><a href="#ref-9">9</a></sup> </th><th align=left colspan=1 rowspan=1 valign=top><a name=d36661e344 class=n-a></a>EAU recommendations</th><th align=left colspan=1 rowspan=1 valign=top><a name=d36661e347 class=n-a></a>AUA definition<sup><a href="#ref-10">10</a></sup> </th><th align=left colspan=1 rowspan=1 valign=top><a name=d36661e354 class=n-a></a>AUA recommendations</th></tr></thead><tbody><a name=d36661e359 class=n-a></a><tr><a name=d36661e361 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e363 class=n-a></a> <span style="text-decoration: underline">Low</span> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e369 class=n-a></a>•&nbsp;&nbsp;Primary,<br class=br>•&nbsp;&nbsp;Solitary (&lt;3 cm),<br class=br>•&nbsp;&nbsp;Low-grade/G1, <span style="text-decoration: underline">and</span> <br class=br>•&nbsp;&nbsp;Ta</td><td align=left colspan=1 rowspan=1><a name=d36661e381 class=n-a></a>•&nbsp;&nbsp;Single immediate post-TUR<br class=br>instillation of chemotherapy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e386 class=n-a></a>•&nbsp;&nbsp;Solitary &lt;3 cm,<br class=br>•&nbsp;&nbsp;Low-grade, <span style="text-decoration: underline">and</span><br class=br>•&nbsp;&nbsp;Ta</td><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e395 class=n-a></a>•&nbsp;&nbsp;Single immediate post-TUR<br class=br>instillation of chemotherapy</td></tr><tr><a name=d36661e401 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e403 class=n-a></a> <span style="text-decoration: underline">Intermediate</span> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e409 class=n-a></a>•&nbsp;&nbsp;Any disease not fitting<br class=br>low- or high-risk criteria</td><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e414 class=n-a></a>•&nbsp;&nbsp;Single immediate post-TUR<br class=br>instillation of chemotherapy,<br class=br>and <span style="text-decoration: underline">either</span><br class=br>•&nbsp;&nbsp;Induction chemotherapy for<br class=br>1 year, <span style="text-decoration: underline">or</span><br class=br>•&nbsp;&nbsp;Induction BCG with 1 year of<br class=br>maintenance therapy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e434 class=n-a></a>•&nbsp;&nbsp;Low-grade Ta<br class=br>recurrence &lt;1 year<br class=br>•&nbsp;&nbsp;Solitary low-grade Ta<br class=br>&gt;3 cm,<br class=br>•&nbsp;&nbsp;Multifocal low-grade<br class=br>Ta,<br class=br>•&nbsp;&nbsp;High-grade Ta ≤3 cm,<br class=br><span style="text-decoration: underline">or</span><br class=br>•&nbsp;&nbsp;Low-grade T1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e455 class=n-a></a>•&nbsp;&nbsp;Single immediate post-TUR<br class=br>instillation of chemotherapy,<br class=br>and <span style="text-decoration: underline">either</span><br class=br>•&nbsp;&nbsp;Induction chemotherapy with<br class=br>or without maintenance, <span style="text-decoration: underline">or</span><br class=br>•&nbsp;&nbsp;Induction BCG with<br class=br>maintenance</td></tr><tr><a name=d36661e476 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e478 class=n-a></a> <span style="text-decoration: underline">High</span> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e484 class=n-a></a>•&nbsp;&nbsp;Any T1, <span style="text-decoration: underline">or</span><br class=br>•&nbsp;&nbsp;High-grade/G3, <span style="text-decoration: underline">or</span><br class=br>•&nbsp;&nbsp;CIS present, <span style="text-decoration: underline">or</span><br class=br>•&nbsp;&nbsp;Multiple, recurrent,<br class=br>large (&gt;3 cm), papillary<br class=br>(Ta), low-grade/G1 or<br class=br>G2 tumors</td><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e506 class=n-a></a>•&nbsp;&nbsp;Single immediate post-TUR<br class=br>instillation of chemotherapy,<br class=br>and <span style="text-decoration: underline">either</span><br class=br>•&nbsp;&nbsp;Induction BCG with 1–3 years<br class=br>of maintenance therapy, <span style="text-decoration: underline">or</span><br class=br>•&nbsp;&nbsp;Immediate radical<br class=br>cystectomy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e526 class=n-a></a>•&nbsp;&nbsp;High-grade T1<br class=br>•&nbsp;&nbsp;Recurrent high-grade<br class=br>Ta<br class=br>•&nbsp;&nbsp;High-grade Ta &gt;3 cm<br class=br>•&nbsp;&nbsp;CIS<br class=br>•&nbsp;&nbsp;Any high-grade<br class=br>failing BCG<br class=br>•&nbsp;&nbsp;Variant histology<br class=br>•&nbsp;&nbsp;LVI<br class=br>•&nbsp;&nbsp;High-grade prostatic<br class=br>urethral involvement</td><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e550 class=n-a></a>•&nbsp;&nbsp;Induction BCG with<br class=br>maintenance therapy, <span style="text-decoration: underline">or</span><br class=br>•&nbsp;&nbsp;Immediate radical cystectomy<br class=br>for highest risk features (with<br class=br>LVI, variant histology, T1 with<br class=br>CIS, persistent T1 on re-TUR)</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d36661e570 class=n-a></a><p id=d36661e572> AUA, American Urological Association; BCG, bacillus Calmette-Guérin; CIS, carcinoma <i>in situ</i>; EAU, European Association of Urology; LVI, lymphovascular invasion; TUR, transurethral resection</p></div></div></div><p class="" id=d36661e581>There is general agreement among urological organizations that a more-conservative approach to treatment (cystoscopic resection and single-dose intravesical chemotherapy) is warranted for low-risk tumors (solitary, low-grade, papillary), while the high-risk group (multifocal high-grade, CIS, or any T1) should be managed aggressively through the use of intravesical immunotherapy, and even radical cystectomy in some cases<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>. This leaves a broad middle ground for intermediate-risk disease, representing a spectrum ranging from a small, recurrent low-grade papillary tumor to large treatment-resistant low-grade tumors to small high-grade lesions. In order to more effectively tailor an appropriate treatment regimen for these patients, further substratification of intermediate-risk bladder cancer has been proposed by an international consortium of bladder cancer experts using a simple scoring system based on four main tumor features (<a href="#f1">Figure 1</a>)<sup><a href="#ref-35">35</a></sup>.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16224/afb43b46-19e1-4631-b79d-a13c3c84e8aa_figure1.gif"><img alt="afb43b46-19e1-4631-b79d-a13c3c84e8aa_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16224/afb43b46-19e1-4631-b79d-a13c3c84e8aa_figure1.gif"></a><div class=caption><h3>Figure 1. Proposed substratification of intermediate-risk non-muscle-invasive bladder cancer (NMIBC) based on the recommendations of the International Bladder Cancer Group<sup><a href="#ref-35">35</a></sup>.</h3><p id=d36661e612>BCG, bacillus Calmette-Guérin; TURBT, transurethral resection of bladder tumor.</p></div></div></div><div class=section><a name=d36661e620 class=n-a></a><h3 class=section-title>Muscle-invasive bladder cancer</h3><p class="" id=d36661e625>MIBC is often treated as a single disease entity with only one acceptable therapy in the form of neoadjuvant chemotherapy followed by radical cystectomy with urinary diversion and lymphadenectomy<sup><a href="#ref-36">36</a></sup>. However, risk assessment can be applied before or after definitive therapy to identify which patients require the most aggressive approach, specifically those that include adjuvant treatments with significant added toxicity. For example, the decision to delay radical cystectomy so that neoadjuvant chemotherapy can be administered for a small—5% absolute improvement in overall survival at 5 years—but statistically significant benefit can be more precisely applied only to patients with the highest chance of seeing a benefit<sup><a href="#ref-37">37</a></sup>. This topic will be re-addressed in more detail in a later section. Although lacking consensus recommendations for risk grouping from any major urological societies, the stratification and personalization of MIBC therapy is on the verge of a significant paradigm shift supported by a growing body of genomic data.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36661e640>Pathologic subtypes</h2><p class="" id=d36661e643>The most common histology of bladder cancer is urothelial carcinoma (~90%) followed by squamous, adenocarcinoma, micropapillary, small cell, and other rare tumors<sup><a href="#ref-38">38</a></sup>. Not all urothelial carcinoma exists in pure form; instead divergent differentiation may occur within the tumor exhibiting different morphology and labeled as “variant histology”<sup><a href="#ref-5">5</a></sup>. Of these variants, several are worth noting, as certain subtypes are known to be associated with a more aggressive clinical course. When taken as a group, variant histology is associated with more advanced stage at diagnosis and may not be amenable to standard treatment algorithms, even when adjusting for stage. For instance, plasmacytoid is particularly aggressive with up to 90% diagnosed with extension outside of the bladder (≥T3) and poor responsiveness to cisplatinum-based adjuvant chemotherapy following radical cystectomy<sup><a href="#ref-39">39</a>–<a href="#ref-41">41</a></sup>. Early cystectomy appears to offer survival advantage for micropapillary disease, even for clinical stage T1, because of a high rate of pathologic upstaging and node positivity<sup><a href="#ref-42">42</a>–<a href="#ref-46">46</a></sup>. Squamous differentiation, the most recognized subtype, and glandular are often reported on pathology reports; however, clinical outcomes are no different than those for conventional urothelial carcinoma<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>. These should also be recognized as very different to pure squamous cell carcinoma and adenocarcinoma of the bladder, which are distinct histologic entities lacking urothelial components<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup>. Other less-common variants worth mentioning include nested, lymphoepithelioma-like, and small cell, the latter being morphologically similar to the lung cancer version and sharing the same aggressive clinical course<sup><a href="#ref-51">51</a>,<a href="#ref-52">52</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36661e693>Molecular subtyping</h2><p class="" id=d36661e696>MIBC ranks among the most highly mutated cancers, with frequencies similar to non-small cell lung cancers and head and neck squamous cell carcinoma, resulting in a heterogeneous mutational profile involving numerous cellular pathways<sup><a href="#ref-53">53</a>–<a href="#ref-56">56</a></sup>. Investigators from around the world have taken on the task of genetically characterizing MIBC samples, resulting in the publication of several major molecular classification systems (the Cancer Genome Atlas [TCGA], Lund, University of North Carolina, MD Anderson, etc.)<sup><a href="#ref-55">55</a>,<a href="#ref-57">57</a>–<a href="#ref-59">59</a></sup>. Each analysis yielded groups of tumors enriched with certain mutations that shared common features with other carcinomas, specifically the breast cancer “basal” and “luminal” subtypes, which led to similarities in the naming schemes. Broadly speaking, basal tumors tend to exhibit a more aggressive phenotype than do luminal tumors and are more prone to metastasis at the time of diagnosis<sup><a href="#ref-55">55</a>–<a href="#ref-60">60</a></sup>. The major publications on this topic have each included a classification system with more-or-less overlap in the mutational profile—i.e. basal-like (UNC), UroB (Lund), Cluster III (TCGA), etc.—that correlates with clinical outcomes. An effort to achieve consensus definitions for all subtypes is underway, thus far producing the Basal-Squamous-like group (BASQ) with elevated <i>KRT5/6</i> and <i>KRT14</i> expression but low <i>FOXA1</i> and <i>GATA3</i> expression<sup><a href="#ref-61">61</a></sup>. By using the information from cohorts like TCGA, several researchers have sought to define the prognostic significance of these genetic mutations through the creation of molecular subtypes with correlation with clinical outcomes<sup><a href="#ref-56">56</a>–<a href="#ref-58">58</a>,<a href="#ref-62">62</a>,<a href="#ref-63">63</a></sup>.</p><p class="" id=d36661e753>The association of molecular subtypes with response to bladder cancer therapy is certain to help guide treatment in the near future: for instance, which patients are most likely to benefit from neoadjuvant chemotherapy prior to surgery or response to immunotherapy over conventional chemotherapy<sup><a href="#ref-56">56</a>,<a href="#ref-57">57</a>,<a href="#ref-64">64</a></sup>. Systemic therapy for bladder cancer can then be more carefully tailored to the individual patient using information obtained from genetic sequencing to select the best candidates for a given treatment regimen (<a href="#f2">Figure 2</a>). For example, tumors exhibiting mutations in genes associated with DNA damage repair (i.e. <i>ERCC2</i>, <i>ERBB2</i>, <i>ATM</i>, and <i>RB1</i>) or those grouped into the basal/squamous subtype display a greater degree of cisplatinum sensitivity as demonstrated by more favorable clinical outcomes among these patients<sup><a href="#ref-56">56</a>,<a href="#ref-57">57</a>,<a href="#ref-65">65</a>–<a href="#ref-68">68</a></sup>. The luminal-papillary and luminal-infiltrated subtypes, on the other hand, show poor response to neoadjuvant chemotherapy; however, tumors with upregulation of the immune checkpoint markers (luminal-infiltrated and basal/squamous) may benefit from treatment with anti-PD-L1, PD-1, and/or CTLA-4 immunotherapy<sup><a href="#ref-56">56</a>,<a href="#ref-69">69</a></sup>.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16224/afb43b46-19e1-4631-b79d-a13c3c84e8aa_figure2.gif"><img alt="afb43b46-19e1-4631-b79d-a13c3c84e8aa_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16224/afb43b46-19e1-4631-b79d-a13c3c84e8aa_figure2.gif"></a><div class=caption><h3>Figure 2. Molecular subtypes of muscle-invasive bladder cancer with associated clinicopathologic and genomic characteristics.</h3><p id=d36661e812>Proposed treatment considerations are listed for each subtype based on available clinical data<sup><a href="#ref-53">53</a>–<a href="#ref-57">57</a>,<a href="#ref-63">63</a>,<a href="#ref-64">64</a>,<a href="#ref-66">66</a>–<a href="#ref-69">69</a></sup>. CIS, carcinoma <i>in situ</i>; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; DLX6, distal-less homeobox 6; E2F3, E2F transcription factor 3; EMT, epithelial to mesenchymal transition; FGFR3, fibroblast growth factor receptor 3; FOX, forkhead box; GATA, GATA-binding protein; KRT, keratin; miR-200, microRNA 200; msi1, Musashi homolog 1; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; PLEKHG4B, pleckstrin homology and RhoGEF domain containing G4B; SHH, sonic hedgehog; SNX31, sorting nexin 31; SOX, SRY-box.</p></div></div><p class="" id=d36661e841>The clinical impact of NMIBC is just as significant as that of MIBC, though maybe not as immediate a threat to survival, especially when taking into account rates of progression reaching as high as 50–60%. A considerable amount of information is available on molecular subtyping for NMIBC that is helping researchers hone in on the most important mutations in the evolution of bladder cancer<sup><a href="#ref-59">59</a>,<a href="#ref-70">70</a>,<a href="#ref-71">71</a></sup>. Low-grade bladder tumors would appear to be genetically distinct from high-grade and MIBC, demonstrating highly conserved genetic mutations of <i>FGFR3</i>, <i>PIK3CA</i>, <i>STAG2</i>, and/or the RTK/RAS/RAF pathway<sup><a href="#ref-72">72</a>–<a href="#ref-75">75</a></sup>. High-grade NMIBC, on the other hand, is more like muscle-invasive disease, exhibiting alteration of DNA damage repair genes (<i>ERBB2</i>), cell cycle regulators (<i>p53</i>, <i>RB1</i>, <i>MDM2</i>, and <i>CDKN2A</i>), and chromatin-modifying genes (<i>KDM6A</i> and <i>ARID1A</i>)<sup><a href="#ref-75">75</a></sup>. Molecular subtyping based on transcriptome analysis of 460 NMIBC and 16 MIBC samples by Hedegaard <i>et al</i>. identified three predominant classes of NMIBC, of which class two showed clustering of high-grade and CIS pathology with an increased risk of clinical progression, indicating that this may be a signature warranting more aggressive, definitive therapy upfront<sup><a href="#ref-71">71</a></sup>. The <i>TERT</i> promoter is worth specific attention owing to similar frequency throughout all tumor stages and grades, regardless of tumor aggressiveness or molecular subtype, and likely represents an early event in the development of urothelial neoplasms<sup><a href="#ref-76">76</a>–<a href="#ref-78">78</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36661e918>Personalized approach to bladder cancer therapy</h2><div class=section><a name=d36661e921 class=n-a></a><h3 class=section-title>Intravesical therapies</h3><p class="" id=d36661e926>Instillation of chemotherapy immediately (within 24 hours) following TUR has been proposed as a method of reducing bladder cancer recurrences, specifically for low- and intermediate-risk disease, and is recommended by both the AUA and the EAU guidelines for NMIBC<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>. It is hypothesized to work via two main methods: (1) residual tumor that has not been fully resected will be killed and (2) elimination of free-floating cancerous cells dislodged during resection that may adhere to the urothelium and proliferate in a region separate from the primary<sup><a href="#ref-79">79</a>,<a href="#ref-80">80</a></sup>. The most well-studied agents include mitomycin C, doxorubicin, and epirubicin, all of which have been found to reduce recurrences (HR 0.40–0.65) without impacting progression or survival outcomes<sup><a href="#ref-81">81</a>–<a href="#ref-89">89</a></sup>. This is probably because of the preponderance of low-risk tumors included in the study cohorts, which are already at very low risk of progression to begin with. According to a recent, large meta-analysis, immediate post-resection instillation would appear to be most effective for small (&lt;3 cm), low-grade, papillary tumors with a baseline recurrence rate of &gt;1 year<sup><a href="#ref-89">89</a></sup>. Not all urologists support this mode of treatment owing to the small but catastrophic possibility of chemotherapy leaking into the perivesical space via missed bladder perforation, in some cases resulting in end-stage bladder fibrosis, for the minimal clinical benefit of prolonging time between recurrences of relatively indolent tumors<sup><a href="#ref-90">90</a>,<a href="#ref-91">91</a></sup>. Though the overwhelming majority of available literature may offer support for this viewpoint, Bosscheiter <i>et al</i>. published a prospective, randomized trial of immediate post-operative mitomycin C versus instillation 2 weeks later among more than 2,000 patients across all risk categories, finding an overall reduction in 3-year recurrence (27% versus 36%) and progression (2.7% versus 5.5%)<sup><a href="#ref-92">92</a></sup>. Interestingly, on subgroup analysis, only the intermediate- and high-risk patients—who also received an adjuvant 6- to 12-week course of intravesical mitomycin C—were found to benefit from the immediate post-operative dose.</p><p class="" id=d36661e969>Induction intravesical therapy refers to a period of weekly instillations of chemotherapy (i.e. mitomycin C, epirubicin, gemcitabine, etc.) or immunotherapy (i.e. BCG) following a complete TUR for NMIBC. At this point, TUR followed by a 6-week course of BCG plus 1 to 3 years of appropriate (3-weekly instillations based on SWOG protocol) maintenance therapy is the first-line option for high-risk disease with a proven improvement in disease recurrence and progression<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a>,<a href="#ref-93">93</a>–<a href="#ref-96">96</a></sup>. Intermediate-risk bladder cancer, on the other hand, can be successfully treated with either chemotherapy or immunotherapy; however, BCG must be followed by at least 1 year of maintenance in order to maintain an advantage in recurrence over mitomycin C<sup><a href="#ref-94">94</a>,<a href="#ref-97">97</a></sup>. Furthermore, while only BCG has shown improvement in progression for these patients, the potential side effects should be considered when selecting a treatment strategy<sup><a href="#ref-97">97</a>–<a href="#ref-99">99</a></sup>.</p><p class="" id=d36661e999>Patients who fail an adequate induction course of intravesical therapy, particularly those receiving BCG who are at highest risk for disease progression, pose a therapeutic dilemma: remove the bladder immediately to prevent muscle invasion and possible metastasis or continue local treatment with further instillations. It is preferable to avoid the morbidity and impact on quality of life associated with radical cystectomy; however, there are currently few alternatives in this setting. The lack of a standardized definition of BCG failure, recognizing that not all forms share the same prognosis, has hindered research into this area. To address these shortcomings, an international panel published guidance for clinicians and researchers to aid in creating more uniformity when designing trials and reporting on this group of patients, as well as to differentiate those with poorest prognosis (BCG unresponsive) who may not benefit from further BCG therapy (<a href="#T2">Table 2</a>)<sup><a href="#ref-100">100</a></sup>. The AUA recommends enrolment in clinical trials for patients who have demonstrated BCG unresponsiveness but are unwilling or unable to undergo a radical cystectomy<sup><a href="#ref-11">11</a></sup>. Several such trials have offered promising results, with most reporting short-term reduction in recurrence of approximately 30–50%, but longer follow-up is associated with sharp declines in responsiveness, and, therefore, there is insufficient evidence to support any single approach, and radical cystectomy remains the gold standard in this population<sup><a href="#ref-94">94</a>,<a href="#ref-101">101</a>–<a href="#ref-107">107</a></sup>.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. A classification system for bacillus Calmette-Guérin (BCG) failures<sup><a href="#ref-100">100</a></sup>.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d36661e1038 class=n-a></a><thead><a name=d36661e1040 class=n-a></a><tr><a name=d36661e1042 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d36661e1044 class=n-a></a>Type of failure</th><th align=left colspan=1 rowspan=1 valign=top><a name=d36661e1047 class=n-a></a>Description</th></tr></thead><tbody><a name=d36661e1052 class=n-a></a><tr><a name=d36661e1054 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e1056 class=n-a></a>BCG refractory</td><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e1059 class=n-a></a>Persistence of high-grade disease at 6 months (3 months for T1<br class=br>high grade) following adequate BCG treatment</td></tr><tr><a name=d36661e1065 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e1067 class=n-a></a>BCG relapsing</td><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e1070 class=n-a></a>Recurrence of high-grade disease following adequate BCG<br class=br>treatment with a disease-free period of 6 months</td></tr><tr><a name=d36661e1076 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e1078 class=n-a></a>BCG unresponsive</td><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e1081 class=n-a></a>Includes BCG refractory and BCG relapses within 6 months (12 months<br class=br>for carcinoma <i>in situ</i> patients)</td></tr><tr><a name=d36661e1090 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e1092 class=n-a></a>BCG intolerant</td><td align=left colspan=1 rowspan=1 valign=top><a name=d36661e1095 class=n-a></a>Persistence of high-grade disease in a patient who is unable to<br class=br>tolerate induction BCG secondary to toxicity</td></tr></tbody></table></div></div><div class=section><a name=d36661e1105 class=n-a></a><h3 class=section-title>Early cystectomy for non-muscle-invasive bladder cancer</h3><p class="" id=d36661e1110>Immediate radical cystectomy may be the best treatment option for selected patients with certain adverse “very high-risk” factors found at the time of diagnosis of NMIBC (<a href="#f3">Figure 3</a>). High-volume T1, persistent high-grade T1 on re-TUR, lymphovascular invasion, certain variant histologies (i.e. micropapillary, plasmacytoid, nested), or concomitant CIS have all been associated with increased risk of progression and are best managed with surgery<sup><a href="#ref-108">108</a>–<a href="#ref-113">113</a></sup>. A group from the United Kingdom has designed a prospective, randomized controlled trial, with end of accrual set for March 2018, comparing immediate cystectomy against BCG induction with maintenance therapy for a “very high-risk” population of NMIBC patients<sup><a href="#ref-114">114</a></sup>. Notably excluded from their cohort are any patients with variant histology.</p><a name=f3 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16224/afb43b46-19e1-4631-b79d-a13c3c84e8aa_figure3.gif"><img alt="afb43b46-19e1-4631-b79d-a13c3c84e8aa_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16224/afb43b46-19e1-4631-b79d-a13c3c84e8aa_figure3.gif"></a><div class=caption><h3>Figure 3. Proposed decision model for immediate radical cystectomy in patients with “very high-risk” non-muscle-invasive bladder cancer (NMIBC)<sup><a href="#ref-11">11</a>,<a href="#ref-125">125</a>–<a href="#ref-129">129</a></sup>.</h3><p id=d36661e1147>AUA, American Urological Association; BCG, bacillus Calmette-Guérin; CIS, carcinoma <i>in situ</i>; LVI, lymphovascular invasion; TURBT, transurethral resection of bladder tumor.</p></div></div></div><div class=section><a name=d36661e1158 class=n-a></a><h3 class=section-title>Radiotherapy</h3><p class="" id=d36661e1163>Trimodal bladder-preserving therapy involves complete endoscopic resection of all visible tumor followed by neoadjuvant chemotherapy and definitive whole-bladder external beam radiotherapy. The use of this strategy is not widespread in the United States, but prospective European cohorts have demonstrated comparable disease-specific outcomes when compared to contemporary radical cystectomy cohorts<sup><a href="#ref-115">115</a></sup>. Limited evidence regarding optimal patient selection has identified increased expression of MRE11, a protein involved in the cellular response to radiation damage, as a potential prognostic marker for improved cancer-specific survival following radiotherapy<sup><a href="#ref-116">116</a>,<a href="#ref-117">117</a></sup>.</p></div><div class=section><a name=d36661e1178 class=n-a></a><h3 class=section-title>Timing of chemotherapy for muscle-invasive bladder cancer</h3><p class="" id=d36661e1183>Muscle invasion at diagnosis of bladder cancer is a poor prognostic indicator best treated with neoadjuvant cisplatinum-based multi-agent chemotherapy followed by radical cystectomy according to evidence from several phase III clinical trials<sup><a href="#ref-118">118</a>–<a href="#ref-121">121</a></sup>. Disease status on final pathology is strongly correlated with oncologic outcomes, and neoadjuvant therapy leads to significant downstaging, including rates of complete response in the range of 30–40% compared to only 15% with surgery alone<sup><a href="#ref-119">119</a></sup>. However, this still leaves a large portion of patients who will not derive benefit, instead undergoing unnecessary toxic therapy while at the same time delaying surgery. Risk stratification can be useful in this setting by selecting those patients with the highest risk (pre-operative T3b–T4, hydroureteronephrosis, lymphovascular invasion, and specific histologic variants) for poor outcomes after cystectomy and only administering neoadjuvant chemotherapy to this subgroup (<a href="#f4">Figure 4</a>)<sup><a href="#ref-122">122</a>,<a href="#ref-123">123</a></sup>. Likewise, post-operative chemotherapy (i.e. adjuvant) can be administered in patients with proven pathologic predictors of developing metastasis, though evidence to support its use is lacking. One study (EORTC 30994) was able to show an improvement in progression-free survival; however, there was no statistically significant impact on overall survival<sup><a href="#ref-124">124</a></sup>.</p><a name=f4 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/16224/afb43b46-19e1-4631-b79d-a13c3c84e8aa_figure4.gif"><img alt="afb43b46-19e1-4631-b79d-a13c3c84e8aa_figure4.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/16224/afb43b46-19e1-4631-b79d-a13c3c84e8aa_figure4.gif"></a><div class=caption><h3>Figure 4. Current MD Anderson Cancer Center algorithm for determining which patients should receive neoadjuvant chemotherapy versus immediate radical cystectomy.</h3><p id=d36661e1221>Inclusion of molecular markers for further risk stratification is pending clinical validation<sup><a href="#ref-37">37</a></sup>. MIBC, muscle-invasive bladder cancer.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36661e1236>Conclusions</h2><p class="" id=d36661e1239>The appropriate management of bladder cancer patients relies heavily upon risk stratification to personalize the therapy for the patient. Currently, clinicopathologic features are the cornerstone of the most widely used risk assessment tools with ample room for improvement. Advances in genetic sequencing of tumors has led to classification systems based on the mutational profile of each individual, offering prognostic information. As these data expand, it is feasible that in the near future this could be integrated to provide guidance that is truly “next generation”.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d36661e1245>Abbreviations</h2><p class="" id=d36661e1248>AUA, American Urological Association; BCG, bacillus Calmette-Guérin; CIS, carcinoma <i>in situ</i>; CUETO, Spanish Urological Club for Oncological Treatment; EAU, European Association of Urology; EORTC, European Organization for Research and Treatment of Cancer; MIBC, muscle-invasive bladder cancer; NMIBC, non-muscle-invasive bladder cancer; SWOG, Southwest Oncology Group; TCGA, the Cancer Genome Atlas; TUR, transurethral resection</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d36661e1 class=n-a></a><h2 class=main-title id=d37061>Competing interests</h2><p class=metadata-entry><a name=d36661e90 class=n-a></a><p id=d36661e91> AMK is a consultant to TMC Innovation, Merck, BMS, Arquer, MDxHealth, Photocure, Theralase, Cepheid, Medac, Asieris, Pfizer, and Astra Zeneca and has received research funding from FKD, Merck, Telesta, and Adolo. JTM has no competing interests to declare.</p></p></div><div class=back-section><a name=d36661e1 class=n-a></a><h2 class=main-title id=d37063>Grant information</h2><p>AMK is supported by the Wayne B. Duddlesten Professorship and a Floyd Family Foundation Grant.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d36661e1258 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d37492>References</h2><div class="section ref-list"><a name=d36661e1258 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d36661e1265 class=n-a></a>Burger M, Catto JW, Dalbagni G, <i> et al.</i>: Epidemiology and risk factors of urothelial bladder cancer. <i>Eur Urol.</i> 2013; <b>63</b>(2): 234–41. <a target=xrefwindow id=d36661e1276 href="http://www.ncbi.nlm.nih.gov/pubmed/22877502">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1279 href="http://dx.doi.org/10.1016/j.eururo.2012.07.033">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732444477"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e1288 class=n-a></a>Siegel RL, Miller KD, Jemal A: Cancer statistics, 2018. <i>CA Cancer J Clin.</i> 2018; <b>68</b>(1): 7–30. <a target=xrefwindow id=d36661e1296 href="http://www.ncbi.nlm.nih.gov/pubmed/29313949">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1299 href="http://dx.doi.org/10.3322/caac.21442">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732444477">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d36661e1312 class=n-a></a>Torre LA, Bray F, Siegel RL, <i> et al.</i>: Global cancer statistics, 2012. <i>CA Cancer J Clin.</i> 2015; <b>65</b>(2): 87–108. <a target=xrefwindow id=d36661e1323 href="http://www.ncbi.nlm.nih.gov/pubmed/25651787">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1326 href="http://dx.doi.org/10.3322/caac.21262">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d36661e1335 class=n-a></a>American Joint Committee on Cancer: AJCC cancer staging manual. Eighth edition. Amin MB, Edge SB, ed. Switzerland: Springer; 2017. <a target=xrefwindow id=d36661e1337 href="https://www.springer.com/in/book/9783319406176">Reference Source</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d36661e1346 class=n-a></a>Humphrey PA, Moch H, Cubilla AL, <i> et al.</i>: The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. <i>Eur Urol.</i> 2016; <b>70</b>(1): 106–19. <a target=xrefwindow id=d36661e1357 href="http://www.ncbi.nlm.nih.gov/pubmed/26996659">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1360 href="http://dx.doi.org/10.1016/j.eururo.2016.02.028">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d36661e1370 class=n-a></a>Divrik RT, Yildirim U, Zorlu F, <i> et al.</i>: The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. <i>J Urol.</i> 2006; <b>175</b>(5): 1641–4. <a target=xrefwindow id=d36661e1381 href="http://www.ncbi.nlm.nih.gov/pubmed/16600720">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1384 href="http://dx.doi.org/10.1016/S0022-5347(05)01002-5">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725866283"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e1393 class=n-a></a>Gendy R, Delprado W, Brenner P, <i> et al.</i>: Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series. <i>BJU Int.</i> 2016; <b>117 Suppl 4</b>: 54–9. <a target=xrefwindow id=d36661e1404 href="http://www.ncbi.nlm.nih.gov/pubmed/26486968">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1407 href="http://dx.doi.org/10.1111/bju.13265">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725866283">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d36661e1420 class=n-a></a>Lazica DA, Roth S, Brandt AS, <i> et al.</i>: Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center. <i>Urol Int.</i> 2014; <b>92</b>(2): 131–5. <a target=xrefwindow id=d36661e1431 href="http://www.ncbi.nlm.nih.gov/pubmed/23988813">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1434 href="http://dx.doi.org/10.1159/000353089">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d36661e1443 class=n-a></a>Cumberbatch MGK, Foerster B, Catto JWF, <i> et al.</i>: Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. <i>Eur Urol.</i> 2018; <b>73</b>(6): 925–33. <a target=xrefwindow id=d36661e1454 href="http://www.ncbi.nlm.nih.gov/pubmed/29523366">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1457 href="http://dx.doi.org/10.1016/j.eururo.2018.02.014">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d36661e1466 class=n-a></a>Babjuk M, Böhle A, Burger M, <i> et al.</i>: EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. <i>Eur Urol.</i> 2017; <b>71</b>(3): 447–61. <a target=xrefwindow id=d36661e1477 href="http://www.ncbi.nlm.nih.gov/pubmed/27324428">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1480 href="http://dx.doi.org/10.1016/j.eururo.2016.05.041">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d36661e1489 class=n-a></a>Chang SS, Boorjian SA, Chou R, <i> et al.</i>: Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. <i>J Urol.</i> 2016; <b>196</b>(4): 1021–9. <a target=xrefwindow id=d36661e1500 href="http://www.ncbi.nlm.nih.gov/pubmed/27317986">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1503 href="http://dx.doi.org/10.1016/j.juro.2016.06.049">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d36661e1513 class=n-a></a>Burger M, Grossman HB, Droller M, <i> et al.</i>: Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. <i>Eur Urol.</i> 2013; <b>64</b>(5): 846–54. <a target=xrefwindow id=d36661e1524 href="http://www.ncbi.nlm.nih.gov/pubmed/23602406">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1527 href="http://dx.doi.org/10.1016/j.eururo.2013.03.059">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729281798"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e1536 class=n-a></a>Chang TC, Marcq G, Kiss B, <i> et al.</i>: Image-Guided Transurethral Resection of Bladder Tumors - Current Practice and Future Outlooks. <i>Bladder Cancer.</i> 2017; <b>3</b>(3): 149–59. <a target=xrefwindow id=d36661e1547 href="http://www.ncbi.nlm.nih.gov/pubmed/28824942">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1550 href="http://dx.doi.org/10.3233/BLC-170119">Publisher Full Text </a> | <a target=xrefwindow id=d36661e1554 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5545914">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729281798">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1166610"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e1567 class=n-a></a>Denzinger S, Burger M, Walter B, <i> et al.</i>: Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. <i>Urology.</i> 2007; <b>69</b>(4): 675–9. <a target=xrefwindow id=d36661e1578 href="http://www.ncbi.nlm.nih.gov/pubmed/17445650">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1581 href="http://dx.doi.org/10.1016/j.urology.2006.12.023">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1166610">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d36661e1594 class=n-a></a>Herr HH: Narrow band imaging cystoscopy. <i>Urol Oncol.</i> 2011; <b>29</b>(4): 353–7. <a target=xrefwindow id=d36661e1602 href="http://www.ncbi.nlm.nih.gov/pubmed/21858935">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1605 href="http://dx.doi.org/10.1016/j.urolonc.2010.12.002">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726942591"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e1614 class=n-a></a>Kang W, Cui Z, Chen Q, <i> et al.</i>: Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysis. <i>Oncotarget.</i> 2017; <b>8</b>(14): 23880–90. <a target=xrefwindow id=d36661e1625 href="http://www.ncbi.nlm.nih.gov/pubmed/27823975">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1628 href="http://dx.doi.org/10.18632/oncotarget.13054">Publisher Full Text </a> | <a target=xrefwindow id=d36661e1632 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5410352">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726942591">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d36661e1645 class=n-a></a>Lee JY, Cho KS, Kang DH, <i> et al.</i>: A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging. <i>BMC Cancer.</i> 2015; <b>15</b>: 566. <a target=xrefwindow id=d36661e1656 href="http://www.ncbi.nlm.nih.gov/pubmed/26232037">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1659 href="http://dx.doi.org/10.1186/s12885-015-1571-8">Publisher Full Text </a> | <a target=xrefwindow id=d36661e1663 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4521364">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d36661e1673 class=n-a></a>Rink M, Babjuk M, Catto JW, <i> et al.</i>: Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. <i>Eur Urol.</i> 2013; <b>64</b>(4): 624–38. <a target=xrefwindow id=d36661e1684 href="http://www.ncbi.nlm.nih.gov/pubmed/23906669">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1687 href="http://dx.doi.org/10.1016/j.eururo.2013.07.007">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726721062"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e1696 class=n-a></a>Rolevich AI, Zhegalik AG, Mokhort AA, <i> et al.</i>: Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer. <i>World J Urol.</i> 2017; <b>35</b>(5): 745–52. <a target=xrefwindow id=d36661e1707 href="http://www.ncbi.nlm.nih.gov/pubmed/27604374">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1710 href="http://dx.doi.org/10.1007/s00345-016-1927-y">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726721062">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d36661e1723 class=n-a></a>Chlapoutakis K, Theocharopoulos N, Yarmenitis S, <i> et al.</i>: Performance of computed tomographic urography in diagnosis of upper urinary tract urothelial carcinoma, in patients presenting with hematuria: Systematic review and meta-analysis. <i>Eur J Radiol.</i> 2010; <b>73</b>(2): 334–8. <a target=xrefwindow id=d36661e1734 href="http://www.ncbi.nlm.nih.gov/pubmed/19058939">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1737 href="http://dx.doi.org/10.1016/j.ejrad.2008.10.026">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d36661e1746 class=n-a></a>Cowan NC, Turney BW, Taylor NJ, <i> et al.</i>: Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. <i>BJU Int.</i> 2007; <b>99</b>(6): 1363–70. <a target=xrefwindow id=d36661e1757 href="http://www.ncbi.nlm.nih.gov/pubmed/17428251">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1760 href="http://dx.doi.org/10.1111/j.1464-410X.2007.06766.x">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d36661e1769 class=n-a></a>Froemming A, Potretzke T, Takahashi N, <i> et al.</i>: Upper tract urothelial cancer. <i>Eur J Radiol.</i> 2018; <b>98</b>: 50–60. <a target=xrefwindow id=d36661e1780 href="http://www.ncbi.nlm.nih.gov/pubmed/29279170">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1783 href="http://dx.doi.org/10.1016/j.ejrad.2017.10.021">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730592112"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e1792 class=n-a></a>Rouprêt M, Babjuk M, Compérat E, <i> et al.</i>: European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. <i>Eur Urol.</i> 2018; <b>73</b>(1): 111–22. <a target=xrefwindow id=d36661e1803 href="http://www.ncbi.nlm.nih.gov/pubmed/28867446">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1806 href="http://dx.doi.org/10.1016/j.eururo.2017.07.036">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730592112">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d36661e1820 class=n-a></a>Takahashi N, Glockner JF, Hartman RP, <i> et al.</i>: Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. <i>J Urol.</i> 2010; <b>183</b>(4): 1330–65. <a target=xrefwindow id=d36661e1831 href="http://www.ncbi.nlm.nih.gov/pubmed/20171676">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1834 href="http://dx.doi.org/10.1016/j.juro.2009.12.031">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d36661e1843 class=n-a></a>Palou J, Rodríguez-Rubio F, Huguet J, <i> et al.</i>: Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. <i>J Urol.</i> 2005; <b>174</b>(3): 859–61; discussion 861. <a target=xrefwindow id=d36661e1854 href="http://www.ncbi.nlm.nih.gov/pubmed/16093970">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1857 href="http://dx.doi.org/10.1097/01.ju.0000169424.79702.6d">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d36661e1866 class=n-a></a>Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, <i> et al.</i>: Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. <i>J Urol.</i> 2000; <b>164</b>(4): 1183–7. <a target=xrefwindow id=d36661e1877 href="http://www.ncbi.nlm.nih.gov/pubmed/10992362">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1880 href="http://dx.doi.org/10.1016/S0022-5347(05)67137-6">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/3246962"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e1889 class=n-a></a>Fernandez-Gomez J, Madero R, Solsona E, <i> et al.</i>: Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. <i>J Urol.</i> 2009; <b>182</b>(5): 2195–203. <a target=xrefwindow id=d36661e1900 href="http://www.ncbi.nlm.nih.gov/pubmed/19758621">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1903 href="http://dx.doi.org/10.1016/j.juro.2009.07.016">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/3246962">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d36661e1916 class=n-a></a>Sylvester RJ, van der Meijden AP, Oosterlinck W, <i> et al.</i>: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. <i>Eur Urol.</i> 2006; <b>49</b>(3): 466–5; discussion 475–7. <a target=xrefwindow id=d36661e1927 href="http://www.ncbi.nlm.nih.gov/pubmed/16442208">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1930 href="http://dx.doi.org/10.1016/j.eururo.2005.12.031">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d36661e1939 class=n-a></a>Fernandez-Gomez J, Madero R, Solsona E, <i> et al.</i>: The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. <i>Eur Urol.</i> 2011; <b>60</b>(3): 423–30. <a target=xrefwindow id=d36661e1950 href="http://www.ncbi.nlm.nih.gov/pubmed/21621906">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1953 href="http://dx.doi.org/10.1016/j.eururo.2011.05.033">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d36661e1963 class=n-a></a>Hernández V, De La Peña E, Martin MD, <i> et al.</i>: External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer. <i>World J Urol.</i> 2011; <b>29</b>(4): 409–14. <a target=xrefwindow id=d36661e1974 href="http://www.ncbi.nlm.nih.gov/pubmed/21190023">PubMed Abstract </a> | <a target=xrefwindow id=d36661e1977 href="http://dx.doi.org/10.1007/s00345-010-0635-2">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d36661e1986 class=n-a></a>Seo KW, Kim BH, Park CH, <i> et al.</i>: The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus calmette-guerin instillation. <i>Korean J Urol.</i> 2010; <b>51</b>(3): 165–70. <a target=xrefwindow id=d36661e1997 href="http://www.ncbi.nlm.nih.gov/pubmed/20414391">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2000 href="http://dx.doi.org/10.4111/kju.2010.51.3.165">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2004 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2855454">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d36661e2013 class=n-a></a>Xylinas E, Kent M, Kluth L, <i> et al.</i>: Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. <i>Br J Cancer.</i> 2013; <b>109</b>(6): 1460–6. <a target=xrefwindow id=d36661e2024 href="http://www.ncbi.nlm.nih.gov/pubmed/23982601">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2027 href="http://dx.doi.org/10.1038/bjc.2013.372">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2031 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3776972">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d36661e2040 class=n-a></a>Lamm DL, Blumenstein BA, Crissman JD, <i> et al.</i>: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma <i>in situ</i> transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. <i>J Urol.</i> 2000; <b>163</b>(4): 1124–9. <a target=xrefwindow id=d36661e2054 href="http://www.ncbi.nlm.nih.gov/pubmed/10737480">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2058 href="http://dx.doi.org/10.1016/S0022-5347(05)67707-5">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d36661e2067 class=n-a></a>van Kessel KEM, van der Keur KA, Dyrskjøt L, <i> et al.</i>: Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups. <i>Clin Cancer Res.</i> 2018; <b>24</b>(7): 1586–93. <a target=xrefwindow id=d36661e2078 href="http://www.ncbi.nlm.nih.gov/pubmed/29367430">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2081 href="http://dx.doi.org/10.1158/1078-0432.CCR-17-2719">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d36661e2090 class=n-a></a>Kamat AM, Witjes JA, Brausi M, <i> et al.</i>: Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. <i>J Urol.</i> 2014; <b>192</b>(2): 305–15. <a target=xrefwindow id=d36661e2101 href="http://www.ncbi.nlm.nih.gov/pubmed/24681333">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2104 href="http://dx.doi.org/10.1016/j.juro.2014.02.2573">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2108 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4687397">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d36661e2118 class=n-a></a>Chang SS, Bochner BH, Chou R, <i> et al.</i>: Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. <i>J Urol.</i> 2017; <b>198</b>(3): 552–9. <a target=xrefwindow id=d36661e2129 href="http://www.ncbi.nlm.nih.gov/pubmed/28456635">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2132 href="http://dx.doi.org/10.1016/j.juro.2017.04.086">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2136 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5626446">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d36661e2145 class=n-a></a>Karam JA, Kamat AM: Optimal timing of chemotherapy and cystectomy. <i>F1000 Med Rep.</i> 2010; <b>2</b>: pii: 48. <a target=xrefwindow id=d36661e2153 href="http://www.ncbi.nlm.nih.gov/pubmed/20948836">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2156 href="http://dx.doi.org/10.3410/M2-48">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2159 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2950042">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d36661e2168 class=n-a></a>Hansel DE, Amin MB, Comperat E, <i> et al.</i>: A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. <i>Eur Urol.</i> 2013; <b>63</b>(2): 321–32. <a target=xrefwindow id=d36661e2179 href="http://www.ncbi.nlm.nih.gov/pubmed/23088996">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2182 href="http://dx.doi.org/10.1016/j.eururo.2012.10.008">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d36661e2191 class=n-a></a>Kaimakliotis HZ, Monn MF, Cary KC, <i> et al.</i>: Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm? <i>Urol Oncol.</i> 2014; <b>32</b>(6): 833–8. <a target=xrefwindow id=d36661e2202 href="http://www.ncbi.nlm.nih.gov/pubmed/24954925">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2205 href="http://dx.doi.org/10.1016/j.urolonc.2014.03.008">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d36661e2214 class=n-a></a>Keck B, Stoehr R, Wach S, <i> et al.</i>: The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinoma. <i>Int J Cancer.</i> 2011; <b>129</b>(2): 346–54. <a target=xrefwindow id=d36661e2225 href="http://www.ncbi.nlm.nih.gov/pubmed/20878954">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2228 href="http://dx.doi.org/10.1002/ijc.25700">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d36661e2237 class=n-a></a>Keck B, Wach S, Stoehr R, <i> et al.</i>: Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. <i>BMC Cancer.</i> 2013; <b>13</b>: 71. <a target=xrefwindow id=d36661e2248 href="http://www.ncbi.nlm.nih.gov/pubmed/23394492">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2251 href="http://dx.doi.org/10.1186/1471-2407-13-71">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2255 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3572418">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d36661e2265 class=n-a></a>Fernández MI, Williams SB, Willis DL, <i> et al.</i>: Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. <i>BJU Int.</i> 2017; <b>119</b>(5): 684–91. <a target=xrefwindow id=d36661e2276 href="http://www.ncbi.nlm.nih.gov/pubmed/27753185">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2279 href="http://dx.doi.org/10.1111/bju.13689">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d36661e2288 class=n-a></a>Kamat AM, Dinney CP, Gee JR, <i> et al.</i>: Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. <i>Cancer.</i> 2007; <b>110</b>(1): 62–7. <a target=xrefwindow id=d36661e2299 href="http://www.ncbi.nlm.nih.gov/pubmed/17542024">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2302 href="http://dx.doi.org/10.1002/cncr.22756">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d36661e2311 class=n-a></a>Meeks JJ, Taylor JM, Matsushita K, <i> et al.</i>: Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. <i>BJU Int.</i> 2013; <b>111</b>(8): E325–30. <a target=xrefwindow id=d36661e2322 href="http://www.ncbi.nlm.nih.gov/pubmed/23384236">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2325 href="http://dx.doi.org/10.1111/j.1464-410X.2012.11751.x">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d36661e2334 class=n-a></a>Sui W, Matulay JT, James MB, <i> et al.</i>: Micropapillary Bladder Cancer: Insights from the National Cancer Database. <i>Bladder Cancer.</i> 2016; <b>2</b>(4): 415–23. <a target=xrefwindow id=d36661e2345 href="http://www.ncbi.nlm.nih.gov/pubmed/28035322">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2348 href="http://dx.doi.org/10.3233/BLC-160066">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2352 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5181670">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727839067"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e2361 class=n-a></a>Vetterlein MW, Wankowicz SAM, Seisen T, <i> et al.</i>: Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. <i>Cancer.</i> 2017; <b>123</b>(22): 4346–55. <a target=xrefwindow id=d36661e2372 href="http://www.ncbi.nlm.nih.gov/pubmed/28743155">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2375 href="http://dx.doi.org/10.1002/cncr.30907">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727839067">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d36661e2388 class=n-a></a>Amin MB: Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. <i>Mod Pathol.</i> 2009; <b>22 Suppl 2</b>: S96–S118. <a target=xrefwindow id=d36661e2396 href="http://www.ncbi.nlm.nih.gov/pubmed/19494856">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2399 href="http://dx.doi.org/10.1038/modpathol.2009.26">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d36661e2409 class=n-a></a>Mitra AP, Bartsch CC, Bartsch G Jr, <i> et al.</i>: Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. <i>Urol Oncol.</i> 2014; <b>32</b>(2): 117–27. <a target=xrefwindow id=d36661e2420 href="http://www.ncbi.nlm.nih.gov/pubmed/23477878">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2423 href="http://dx.doi.org/10.1016/j.urolonc.2012.08.017">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d36661e2432 class=n-a></a>Abdollah F, Sun M, Jeldres C, <i> et al.</i>: Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis. <i>BJU Int.</i> 2012; <b>109</b>(4): 564–9. <a target=xrefwindow id=d36661e2443 href="http://www.ncbi.nlm.nih.gov/pubmed/21810161">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2446 href="http://dx.doi.org/10.1111/j.1464-410X.2011.10357.x">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d36661e2455 class=n-a></a>Zaghloul MS, Nouh A, Nazmy M, <i> et al.</i>: Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. <i>Urol Oncol.</i> 2006; <b>24</b>(1): 13–20. <a target=xrefwindow id=d36661e2466 href="http://www.ncbi.nlm.nih.gov/pubmed/16414487">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2469 href="http://dx.doi.org/10.1016/j.urolonc.2005.05.027">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731794254"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e2478 class=n-a></a>Warrick JI: Clinical Significance of Histologic Variants of Bladder Cancer. <i>J Natl Compr Canc Netw.</i> 2017; <b>15</b>(10): 1268–74. <a target=xrefwindow id=d36661e2486 href="http://www.ncbi.nlm.nih.gov/pubmed/28982751">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2489 href="http://dx.doi.org/10.6004/jnccn.2017.7027">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731794254">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d36661e2502 class=n-a></a>Lynch SP, Shen Y, Kamat A, <i> et al.</i>: Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. <i>Eur Urol.</i> 2013; <b>64</b>(2): 307–13. <a target=xrefwindow id=d36661e2513 href="http://www.ncbi.nlm.nih.gov/pubmed/22564397">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2516 href="http://dx.doi.org/10.1016/j.eururo.2012.04.020">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2520 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3815632">Free Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718146641"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e2529 class=n-a></a>Kandoth C, McLellan MD, Vandin F, <i> et al.</i>: Mutational landscape and significance across 12 major cancer types. <i>Nature.</i> 2013; <b>502</b>(7471): 333–9. <a target=xrefwindow id=d36661e2540 href="http://www.ncbi.nlm.nih.gov/pubmed/24132290">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2543 href="http://dx.doi.org/10.1038/nature12634">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2547 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3927368">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718146641">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d36661e2561 class=n-a></a>Yap KL, Kiyotani K, Tamura K, <i> et al.</i>: Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of <i>UNC5C</i> and prognostic importance of DNA repair gene mutations on survival. <i>Clin Cancer Res.</i> 2014; <b>20</b>(24): 6605–17. <a target=xrefwindow id=d36661e2575 href="http://www.ncbi.nlm.nih.gov/pubmed/25316812">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2579 href="http://dx.doi.org/10.1158/1078-0432.CCR-14-0257">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2582 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4268280">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718256975"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e2591 class=n-a></a>Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. <i>Nature.</i> 2014; <b>507</b>(7492): 315–22. <a target=xrefwindow id=d36661e2599 href="http://www.ncbi.nlm.nih.gov/pubmed/24476821">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2602 href="http://dx.doi.org/10.1038/nature12965">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2605 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3962515">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718256975">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731932301"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e2618 class=n-a></a>Robertson AG, Kim J, Al-Ahmadie H, <i> et al.</i>: Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell.</i> 2017; <b>171</b>(3): 540–556.e25. <a target=xrefwindow id=d36661e2629 href="http://www.ncbi.nlm.nih.gov/pubmed/28988769">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2632 href="http://dx.doi.org/10.1016/j.cell.2017.09.007">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2636 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5687509">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731932301">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d36661e2649 class=n-a></a>Choi W, Porten S, Kim S, <i> et al.</i>: Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. <i>Cancer Cell.</i> 2014; <b>25</b>(2): 152–65. <a target=xrefwindow id=d36661e2660 href="http://www.ncbi.nlm.nih.gov/pubmed/24525232">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2663 href="http://dx.doi.org/10.1016/j.ccr.2014.01.009">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2667 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4011497">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d36661e2676 class=n-a></a>Damrauer JS, Hoadley KA, Chism DD, <i> et al.</i>: Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. <i>Proc Natl Acad Sci U S A.</i> 2014; <b>111</b>(8): 3110–5. <a target=xrefwindow id=d36661e2687 href="http://www.ncbi.nlm.nih.gov/pubmed/24520177">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2690 href="http://dx.doi.org/10.1073/pnas.1318376111">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2694 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3939870">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d36661e2703 class=n-a></a>Lindgren D, Frigyesi A, Gudjonsson S, <i> et al.</i>: Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. <i>Cancer Res.</i> 2010; <b>70</b>(9): 3463–72. <a target=xrefwindow id=d36661e2714 href="http://www.ncbi.nlm.nih.gov/pubmed/20406976">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2717 href="http://dx.doi.org/10.1158/0008-5472.CAN-09-4213">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d36661e2727 class=n-a></a>Kamat AM, Hahn NM, Efstathiou JA, <i> et al.</i>: Bladder cancer. <i>Lancet.</i> 2016; <b>388</b>(10061): 2796–810. <a target=xrefwindow id=d36661e2738 href="http://www.ncbi.nlm.nih.gov/pubmed/27345655">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2741 href="http://dx.doi.org/10.1016/S0140-6736(16)30512-8">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d36661e2750 class=n-a></a>Lerner SP, McConkey DJ, Hoadley KA, <i> et al.</i>: Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting. <i>Bladder Cancer.</i> 2016; <b>2</b>(1): 37–47. <a target=xrefwindow id=d36661e2761 href="http://www.ncbi.nlm.nih.gov/pubmed/27376123">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2764 href="http://dx.doi.org/10.3233/BLC-150037">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2768 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4927916">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d36661e2777 class=n-a></a>Rebouissou S, Bernard-Pierrot I, de Reyniès A, <i> et al.</i>: EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. <i>Sci Transl Med.</i> 2014; <b>6</b>(244): 244ra91. <a target=xrefwindow id=d36661e2788 href="http://www.ncbi.nlm.nih.gov/pubmed/25009231">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2791 href="http://dx.doi.org/10.1126/scitranslmed.3008970">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727305019"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e2800 class=n-a></a>Sjödahl G, Eriksson P, Liedberg F, <i> et al.</i>: Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. <i>J Pathol.</i> 2017; <b>242</b>(1): 113–25. <a target=xrefwindow id=d36661e2811 href="http://www.ncbi.nlm.nih.gov/pubmed/28195647">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2814 href="http://dx.doi.org/10.1002/path.4886">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2818 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5413843">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727305019">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727490757"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e2831 class=n-a></a>Seiler R, Ashab HAD, Erho N, <i> et al.</i>: Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>Eur Urol.</i> 2017; <b>72</b>(4): 544–54. <a target=xrefwindow id=d36661e2842 href="http://www.ncbi.nlm.nih.gov/pubmed/28390739">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2845 href="http://dx.doi.org/10.1016/j.eururo.2017.03.030">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727490757">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725333784"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e2858 class=n-a></a>Groenendijk FH, de Jong J, Fransen van de Putte EE, <i> et al.</i>: <i>ERBB2</i> Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. <i>Eur Urol.</i> 2016; <b>69</b>(3): 384–8. <a target=xrefwindow id=d36661e2872 href="http://www.ncbi.nlm.nih.gov/pubmed/25636205">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2876 href="http://dx.doi.org/10.1016/j.eururo.2015.01.014">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725333784">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733639775"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e2890 class=n-a></a>Liu D, Plimack ER, Hoffman-Censits J, <i> et al.</i>: Clinical Validation of Chemotherapy Response Biomarker <i>ERCC2</i> in Muscle-Invasive Urothelial Bladder Carcinoma. <i>JAMA Oncol.</i> 2016; <b>2</b>(8): 1094–6. <a target=xrefwindow id=d36661e2904 href="http://www.ncbi.nlm.nih.gov/pubmed/27310333">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2908 href="http://dx.doi.org/10.1001/jamaoncol.2016.1056">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2911 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5515075">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733639775">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725696741"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e2924 class=n-a></a>Plimack ER, Dunbrack RL, Brennan TA, <i> et al.</i>: Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. <i>Eur Urol.</i> 2015; <b>68</b>(6): 959–67. <a target=xrefwindow id=d36661e2935 href="http://www.ncbi.nlm.nih.gov/pubmed/26238431">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2938 href="http://dx.doi.org/10.1016/j.eururo.2015.07.009">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2942 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4764095">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725696741">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718521900"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e2955 class=n-a></a>van Allen EM, Mouw KW, Kim P, <i> et al.</i>: Somatic <i>ERCC2</i> mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. <i>Cancer Discov.</i> 2014; <b>4</b>(10): 1140–53. <a target=xrefwindow id=d36661e2969 href="http://www.ncbi.nlm.nih.gov/pubmed/25096233">PubMed Abstract </a> | <a target=xrefwindow id=d36661e2973 href="http://dx.doi.org/10.1158/2159-8290.CD-14-0623">Publisher Full Text </a> | <a target=xrefwindow id=d36661e2976 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4238969">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718521900">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732026813"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e2989 class=n-a></a>Ren R, Tyryshkin K, Graham CH, <i> et al.</i>: Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance. <i>Oncotarget.</i> 2017; <b>8</b>(41): 70982–1001. <a target=xrefwindow id=d36661e3000 href="http://www.ncbi.nlm.nih.gov/pubmed/29050337">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3003 href="http://dx.doi.org/10.18632/oncotarget.20237">Publisher Full Text </a> | <a target=xrefwindow id=d36661e3007 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5642612">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732026813">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d36661e3020 class=n-a></a>Hurst CD, Alder O, Platt FM, <i> et al.</i>: Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in <i>KDM6A</i> Mutation Frequency. <i>Cancer Cell.</i> 2017; <b>32</b>(5): 701–715.e7. <a target=xrefwindow id=d36661e3034 href="http://www.ncbi.nlm.nih.gov/pubmed/29136510">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3038 href="http://dx.doi.org/10.1016/j.ccell.2017.08.005">Publisher Full Text </a> | <a target=xrefwindow id=d36661e3041 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5774674">Free Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726435681"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e3050 class=n-a></a>Hedegaard J, Lamy P, Nordentoft I, <i> et al.</i>: Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. <i>Cancer Cell.</i> 2016; <b>30</b>(1): 27–42. <a target=xrefwindow id=d36661e3061 href="http://www.ncbi.nlm.nih.gov/pubmed/27321955">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3064 href="http://dx.doi.org/10.1016/j.ccell.2016.05.004">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726435681">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d36661e3078 class=n-a></a>Al Hussain TO, Akhtar M: Molecular basis of urinary bladder cancer. <i>Adv Anat Pathol.</i> 2013; <b>20</b>(1): 53–60. <a target=xrefwindow id=d36661e3086 href="http://www.ncbi.nlm.nih.gov/pubmed/23232572">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3089 href="http://dx.doi.org/10.1097/PAP.0b013e31827bd0ec">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d36661e3098 class=n-a></a>Billerey C, Chopin D, Aubriot-Lorton MH, <i> et al.</i>: Frequent <i>FGFR3</i> mutations in papillary non-invasive bladder (pTa) tumors. <i>Am J Pathol.</i> 2001; <b>158</b>(6): 1955–9. <a target=xrefwindow id=d36661e3112 href="http://www.ncbi.nlm.nih.gov/pubmed/11395371">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3116 href="http://dx.doi.org/10.1016/S0002-9440(10)64665-2">Publisher Full Text </a> | <a target=xrefwindow id=d36661e3119 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1891972">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d36661e3128 class=n-a></a>Liu X, Zhang W, Geng D, <i> et al.</i>: Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis. <i>Genet Mol Res.</i> 2014; <b>13</b>(1): 1109–20. <a target=xrefwindow id=d36661e3139 href="http://www.ncbi.nlm.nih.gov/pubmed/24634132">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3142 href="http://dx.doi.org/10.4238/2014.February.20.12">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727690508"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e3151 class=n-a></a>Pietzak EJ, Bagrodia A, Cha EK, <i> et al.</i>: Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. <i>Eur Urol.</i> 2017; <b>72</b>(6): 952–9. <a target=xrefwindow id=d36661e3162 href="http://www.ncbi.nlm.nih.gov/pubmed/28583311">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3165 href="http://dx.doi.org/10.1016/j.eururo.2017.05.032">Publisher Full Text </a> | <a target=xrefwindow id=d36661e3169 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6007852">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727690508">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d36661e3182 class=n-a></a>Allory Y, Beukers W, Sagrera A, <i> et al.</i>: Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. <i>Eur Urol.</i> 2014; <b>65</b>(2): 360–6. <a target=xrefwindow id=d36661e3193 href="http://www.ncbi.nlm.nih.gov/pubmed/24018021">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3196 href="http://dx.doi.org/10.1016/j.eururo.2013.08.052">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d36661e3205 class=n-a></a>Cheng L, Davidson DD, Wang M, <i> et al.</i>: Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. <i>Histopathology.</i> 2016; <b>69</b>(1): 107–13. <a target=xrefwindow id=d36661e3216 href="http://www.ncbi.nlm.nih.gov/pubmed/26679899">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3219 href="http://dx.doi.org/10.1111/his.12920">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732208457"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e3229 class=n-a></a>Wang CC, Huang CY, Jhuang YL, <i> et al.</i>: Biological significance of <i>TERT</i> promoter mutation in papillary urothelial neoplasm of low malignant potential. <i>Histopathology.</i> 2018; <b>72</b>(5): 795–803. <a target=xrefwindow id=d36661e3243 href="http://www.ncbi.nlm.nih.gov/pubmed/29193225">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3247 href="http://dx.doi.org/10.1111/his.13441">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732208457">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d36661e3260 class=n-a></a>Kaasinen E, Rintala E, Hellström P, <i> et al.</i>: Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. <i>Eur Urol.</i> 2002; <b>42</b>(2): 167–74. <a target=xrefwindow id=d36661e3271 href="http://www.ncbi.nlm.nih.gov/pubmed/12160589">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3274 href="http://dx.doi.org/10.1016/S0302-2838(02)00260-9">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d36661e3283 class=n-a></a>Pode D, Alon Y, Horowitz AT, <i> et al.</i>: The mechanism of human bladder tumor implantation in an <i>in vitro</i> model. <i>J Urol.</i> 1986; <b>136</b>(2): 482–6. <a target=xrefwindow id=d36661e3297 href="http://www.ncbi.nlm.nih.gov/pubmed/3525861">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3301 href="http://dx.doi.org/10.1016/S0022-5347(17)44926-3">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d36661e3310 class=n-a></a>Barghi MR, Rahmani MR, Hosseini Moghaddam SM, <i> et al.</i>: Immediate intravesical instillation of mitomycin C after transurethral resection of bladder tumor in patients with low-risk superficial transitional cell carcinoma of bladder. <i>Urol J.</i> 2006; <b>3</b>(4): 220–4. <a target=xrefwindow id=d36661e3321 href="http://www.ncbi.nlm.nih.gov/pubmed/17559045">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3324 href="http://dx.doi.org/10.22037/uj.v3i4.166">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1160485"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e3333 class=n-a></a>Berrum-Svennung I, Granfors T, Jahnson S, <i> et al.</i>: A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. <i>J Urol.</i> 2008; <b>179</b>(1): 101–5; discussion 105–6. <a target=xrefwindow id=d36661e3344 href="http://www.ncbi.nlm.nih.gov/pubmed/17997459">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3347 href="http://dx.doi.org/10.1016/j.juro.2007.08.166">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1160485">F1000 Recommendation</a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d36661e3360 class=n-a></a>De Nunzio C, Carbone A, Albisinni S, <i> et al.</i>: Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. <i>World J Urol.</i> 2011; <b>29</b>(4): 517–21. <a target=xrefwindow id=d36661e3371 href="http://www.ncbi.nlm.nih.gov/pubmed/21594708">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3374 href="http://dx.doi.org/10.1007/s00345-011-0691-2">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d36661e3384 class=n-a></a>Gudjónsson S, Adell L, Merdasa F, <i> et al.</i>: Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. <i>Eur Urol.</i> 2009; <b>55</b>(4): 773–80. <a target=xrefwindow id=d36661e3395 href="http://www.ncbi.nlm.nih.gov/pubmed/19153001">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3398 href="http://dx.doi.org/10.1016/j.eururo.2009.01.006">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d36661e3407 class=n-a></a>Kang M, Jeong CW, Kwak C, <i> et al.</i>: Single, immediate postoperative instillation of chemotherapy in non-muscle invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials using different drugs. <i>Oncotarget.</i> 2016; <b>7</b>(29): 45479–88. <a target=xrefwindow id=d36661e3418 href="http://www.ncbi.nlm.nih.gov/pubmed/27323781">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3421 href="http://dx.doi.org/10.18632/oncotarget.9991">Publisher Full Text </a> | <a target=xrefwindow id=d36661e3425 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5216735">Free Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d36661e3434 class=n-a></a>Perlis N, Zlotta AR, Beyene J, <i> et al.</i>: Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. <i>Eur Urol.</i> 2013; <b>64</b>(3): 421–30. <a target=xrefwindow id=d36661e3445 href="http://www.ncbi.nlm.nih.gov/pubmed/23830475">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3448 href="http://dx.doi.org/10.1016/j.eururo.2013.06.009">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d36661e3457 class=n-a></a>Solsona E, Iborra I, Ricós JV, <i> et al.</i>: Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. <i>J Urol.</i> 1999; <b>161</b>(4): 1120–3. <a target=xrefwindow id=d36661e3468 href="http://www.ncbi.nlm.nih.gov/pubmed/10081851">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3471 href="http://dx.doi.org/10.1016/S0022-5347(01)61606-9">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d36661e3480 class=n-a></a>Sylvester RJ, Oosterlinck W: An immediate instillation after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: has the evidence changed? <i>Eur Urol.</i> 2009; <b>56</b>(1): 43–5. <a target=xrefwindow id=d36661e3488 href="http://www.ncbi.nlm.nih.gov/pubmed/19375216">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3491 href="http://dx.doi.org/10.1016/j.eururo.2009.03.074">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725572648"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e3500 class=n-a></a>Sylvester RJ, Oosterlinck W, Holmang S, <i> et al.</i>: Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? <i>Eur Urol.</i> 2016; <b>69</b>(2): 231–44. <a target=xrefwindow id=d36661e3511 href="http://www.ncbi.nlm.nih.gov/pubmed/26091833">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3514 href="http://dx.doi.org/10.1016/j.eururo.2015.05.050">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725572648">F1000 Recommendation</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718367739"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e3528 class=n-a></a>Elmamoun MH, Christmas TJ, Woodhouse CR: Destruction of the bladder by single dose Mitomycin C for low-stage transitional cell carcinoma (TCC)--avoidance, recognition, management and consent. <i>BJU Int.</i> 2014; <b>113</b>(5b): E34–8. <a target=xrefwindow id=d36661e3536 href="http://www.ncbi.nlm.nih.gov/pubmed/24053461">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3539 href="http://dx.doi.org/10.1111/bju.12340">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718367739">F1000 Recommendation</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d36661e3552 class=n-a></a>Oddens JR, van der Meijden AP, Sylvester R: One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? <i>Eur Urol.</i> 2004; <b>46</b>(3): 336–8. <a target=xrefwindow id=d36661e3560 href="http://www.ncbi.nlm.nih.gov/pubmed/15306104">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3563 href="http://dx.doi.org/10.1016/j.eururo.2004.05.003">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727807602"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e3572 class=n-a></a>Bosschieter J, Nieuwenhuijzen JA, van Ginkel T, <i> et al.</i>: Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients. <i>Eur Urol.</i> 2018; <b>73</b>(2): 226–32. <a target=xrefwindow id=d36661e3583 href="http://www.ncbi.nlm.nih.gov/pubmed/28705539">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3586 href="http://dx.doi.org/10.1016/j.eururo.2017.06.038">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727807602">F1000 Recommendation</a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d36661e3599 class=n-a></a>Böhle A, Jocham D, Bock PR: Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. <i>J Urol.</i> 2003; <b>169</b>(1): 90–5. <a target=xrefwindow id=d36661e3607 href="http://www.ncbi.nlm.nih.gov/pubmed/12478111">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3610 href="http://dx.doi.org/10.1016/S0022-5347(05)64043-8">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d36661e3619 class=n-a></a>Malmström PU, Sylvester RJ, Crawford DE, <i> et al.</i>: An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. <i>Eur Urol.</i> 2009; <b>56</b>(2): 247–56. <a target=xrefwindow id=d36661e3630 href="http://www.ncbi.nlm.nih.gov/pubmed/19409692">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3633 href="http://dx.doi.org/10.1016/j.eururo.2009.04.038">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d36661e3642 class=n-a></a>Shelley MD, Mason MD, Kynaston H: Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. <i>Cancer Treat Rev.</i> 2010; <b>36</b>(3): 195–205. <a target=xrefwindow id=d36661e3650 href="http://www.ncbi.nlm.nih.gov/pubmed/20079574">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3653 href="http://dx.doi.org/10.1016/j.ctrv.2009.12.005">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d36661e3663 class=n-a></a>Shelley MD, Wilt TJ, Court J, <i> et al.</i>: Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. <i>BJU Int.</i> 2004; <b>93</b>(4): 485–90. <a target=xrefwindow id=d36661e3674 href="http://www.ncbi.nlm.nih.gov/pubmed/15008714">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3677 href="http://dx.doi.org/10.1111/j.1464-410X.2003.04655.x">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d36661e3686 class=n-a></a>Chou R, Selph S, Buckley DI, <i> et al.</i>: Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. <i>J Urol.</i> 2017; <b>197</b>(5): 1189–99. <a target=xrefwindow id=d36661e3697 href="http://www.ncbi.nlm.nih.gov/pubmed/28027868">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3700 href="http://dx.doi.org/10.1016/j.juro.2016.12.090">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d36661e3709 class=n-a></a>Brausi M, Oddens J, Sylvester R, <i> et al.</i>: Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. <i>Eur Urol.</i> 2014; <b>65</b>(1): 69–76. <a target=xrefwindow id=d36661e3720 href="http://www.ncbi.nlm.nih.gov/pubmed/23910233">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3723 href="http://dx.doi.org/10.1016/j.eururo.2013.07.021">Publisher Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d36661e3732 class=n-a></a>Böhle A, Bock PR: Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. <i>Urology.</i> 2004; <b>63</b>(4): 682–6; discussion 686–7. <a target=xrefwindow id=d36661e3740 href="http://www.ncbi.nlm.nih.gov/pubmed/15072879">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3743 href="http://dx.doi.org/10.1016/j.urology.2003.11.049">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d36661e3752 class=n-a></a>Kamat AM, Sylvester RJ, Böhle A, <i> et al.</i>: Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. <i>J Clin Oncol.</i> 2016; <b>34</b>(16): 1935–44. <a target=xrefwindow id=d36661e3763 href="http://www.ncbi.nlm.nih.gov/pubmed/26811532">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3766 href="http://dx.doi.org/10.1200/JCO.2015.64.4070">Publisher Full Text </a> | <a target=xrefwindow id=d36661e3770 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5321095">Free Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d36661e3779 class=n-a></a>Barlow LJ, Benson MC: Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer. <i>Curr Urol Rep.</i> 2013; <b>14</b>(2): 65–70. <a target=xrefwindow id=d36661e3787 href="http://www.ncbi.nlm.nih.gov/pubmed/23378162">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3790 href="http://dx.doi.org/10.1007/s11934-013-0312-2">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d36661e3800 class=n-a></a>Di Lorenzo G, Perdonà S, Damiano R, <i> et al.</i>: Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. <i>Cancer.</i> 2010; <b>116</b>(8): 1893–900. <a target=xrefwindow id=d36661e3811 href="http://www.ncbi.nlm.nih.gov/pubmed/20162706">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3814 href="http://dx.doi.org/10.1002/cncr.24914">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d36661e3823 class=n-a></a>McKiernan JM, Holder DD, Ghandour RA, <i> et al.</i>: Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin treatment failure. <i>J Urol.</i> 2014; <b>192</b>(6): 1633–8. <a target=xrefwindow id=d36661e3834 href="http://www.ncbi.nlm.nih.gov/pubmed/24996128">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3837 href="http://dx.doi.org/10.1016/j.juro.2014.06.084">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d36661e3846 class=n-a></a>Porten SP, Leapman MS, Greene KL: Intravesical chemotherapy in non-muscle-invasive bladder cancer. <i>Indian J Urol.</i> 2015; <b>31</b>(4): 297–303. <a target=xrefwindow id=d36661e3854 href="http://www.ncbi.nlm.nih.gov/pubmed/26604440">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3857 href="http://dx.doi.org/10.4103/0970-1591.166446">Publisher Full Text </a> | <a target=xrefwindow id=d36661e3860 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4626913">Free Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d36661e3869 class=n-a></a>Shelley MD, Jones G, Cleves A, <i> et al.</i>: Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. <i>BJU Int.</i> 2012; <b>109</b>(4): 496–505. <a target=xrefwindow id=d36661e3880 href="http://www.ncbi.nlm.nih.gov/pubmed/22313502">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3883 href="http://dx.doi.org/10.1111/j.1464-410X.2011.10880.x">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d36661e3892 class=n-a></a>Steinberg G, Bahnson R, Brosman S, <i> et al.</i>: Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma <i>in situ</i> of the bladder. The Valrubicin Study Group. <i>J Urol.</i> 2000; <b>163</b>(3): 761–7. <a target=xrefwindow id=d36661e3906 href="http://www.ncbi.nlm.nih.gov/pubmed/10687972">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3910 href="http://dx.doi.org/10.1016/S0022-5347(05)67799-3">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d36661e3919 class=n-a></a>Sternberg IA, Dalbagni G, Chen LY, <i> et al.</i>: Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure. <i>J Urol.</i> 2013; <b>190</b>(5): 1686–91. <a target=xrefwindow id=d36661e3930 href="http://www.ncbi.nlm.nih.gov/pubmed/23665400">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3933 href="http://dx.doi.org/10.1016/j.juro.2013.04.120">Publisher Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d36661e3943 class=n-a></a>Mathieu R, Lucca I, Rouprêt M, <i> et al.</i>: The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. <i>Nat Rev Urol.</i> 2016; <b>13</b>(8): 471–9. <a target=xrefwindow id=d36661e3954 href="http://www.ncbi.nlm.nih.gov/pubmed/27431340">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3957 href="http://dx.doi.org/10.1038/nrurol.2016.126">Publisher Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725298472"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e3966 class=n-a></a>Martin-Doyle W, Leow JJ, Orsola A, <i> et al.</i>: Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. <i>J Clin Oncol.</i> 2015; <b>33</b>(6): 643–50. <a target=xrefwindow id=d36661e3977 href="http://www.ncbi.nlm.nih.gov/pubmed/25559810">PubMed Abstract </a> | <a target=xrefwindow id=d36661e3980 href="http://dx.doi.org/10.1200/JCO.2014.57.6967">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725298472">F1000 Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d36661e3993 class=n-a></a>Willis DL, Fernandez MI, Dickstein RJ, <i> et al.</i>: Clinical outcomes of cT1 micropapillary bladder cancer. <i>J Urol.</i> 2015; <b>193</b>(4): 1129–34. <a target=xrefwindow id=d36661e4004 href="http://www.ncbi.nlm.nih.gov/pubmed/25254936">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4007 href="http://dx.doi.org/10.1016/j.juro.2014.09.092">Publisher Full Text </a> | <a target=xrefwindow id=d36661e4011 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4687395">Free Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d36661e4020 class=n-a></a>Segal R, Yafi FA, Brimo F, <i> et al.</i>: Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? <i>BJU Int.</i> 2012; <b>109</b>(7): 1026–30. <a target=xrefwindow id=d36661e4031 href="http://www.ncbi.nlm.nih.gov/pubmed/21883838">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4034 href="http://dx.doi.org/10.1111/j.1464-410X.2011.10462.x">Publisher Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d36661e4043 class=n-a></a>Mally AD, Tin AL, Lee JK, <i> et al.</i>: Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder. <i>Clin Genitourin Cancer.</i> 2017; pii: S1558-7673(17)30199-4. <a target=xrefwindow id=d36661e4051 href="http://www.ncbi.nlm.nih.gov/pubmed/28802887">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4054 href="http://dx.doi.org/10.1016/j.clgc.2017.07.002">Publisher Full Text </a> | <a target=xrefwindow id=d36661e4057 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5767538">Free Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d36661e4066 class=n-a></a>Ark JT, Keegan KA, Barocas DA, <i> et al.</i>: Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. <i>BJU Int.</i> 2014; <b>113</b>(6): 894–9. <a target=xrefwindow id=d36661e4077 href="http://www.ncbi.nlm.nih.gov/pubmed/24053444">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4080 href="http://dx.doi.org/10.1111/bju.12245">Publisher Full Text </a> | <a target=xrefwindow id=d36661e4084 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3874077">Free Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d36661e4094 class=n-a></a>Oughton JB, Poad H, Twiddy M, <i> et al.</i>: Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study. <i>BMJ Open.</i> 2017; <b>7</b>(8): e017913. <a target=xrefwindow id=d36661e4105 href="http://www.ncbi.nlm.nih.gov/pubmed/28801444">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4108 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5724134">Free Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d36661e4117 class=n-a></a>Mak RH, Hunt D, Shipley WU, <i> et al.</i>: Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. <i>J Clin Oncol.</i> 2014; <b>32</b>(34): 3801–9. <a target=xrefwindow id=d36661e4128 href="http://www.ncbi.nlm.nih.gov/pubmed/25366678">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4131 href="http://dx.doi.org/10.1200/JCO.2014.57.5548">Publisher Full Text </a> | <a target=xrefwindow id=d36661e4135 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4239302">Free Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d36661e4144 class=n-a></a>Choudhury A, Nelson LD, Teo MT, <i> et al.</i>: MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. <i>Cancer Res.</i> 2010; <b>70</b>(18): 7017–26. <a target=xrefwindow id=d36661e4155 href="http://www.ncbi.nlm.nih.gov/pubmed/20843819">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4158 href="http://dx.doi.org/10.1158/0008-5472.CAN-10-1202">Publisher Full Text </a> | <a target=xrefwindow id=d36661e4162 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2941719">Free Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d36661e4171 class=n-a></a>Laurberg JR, Brems-Eskildsen AS, Nordentoft I, <i> et al.</i>: Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. <i>BJU Int.</i> 2012; <b>110</b>(11 Pt C): E1228–36. <a target=xrefwindow id=d36661e4182 href="http://www.ncbi.nlm.nih.gov/pubmed/23046361">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4185 href="http://dx.doi.org/10.1111/j.1464-410X.2012.11564.x">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/3138956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e4194 class=n-a></a>Grossman HB, Natale RB, Tangen CM, <i> et al.</i>: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. <i>N Engl J Med.</i> 2003; <b>349</b>(9): 859–66. <a target=xrefwindow id=d36661e4205 href="http://www.ncbi.nlm.nih.gov/pubmed/12944571">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4208 href="http://dx.doi.org/10.1056/NEJMoa022148">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/3138956">F1000 Recommendation</a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d36661e4221 class=n-a></a>Advanced Bladder Cancer (ABC) Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. <i>Eur Urol.</i> 2005; <b>48</b>(2): 202–5; discussion 205–6. <a target=xrefwindow id=d36661e4229 href="http://www.ncbi.nlm.nih.gov/pubmed/15939524">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4232 href="http://dx.doi.org/10.1016/j.eururo.2005.04.006">Publisher Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d36661e4242 class=n-a></a>Yuh BE, Ruel N, Wilson TG, <i> et al.</i>: Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. <i>J Urol.</i> 2013; <b>189</b>(5): 1682–6. <a target=xrefwindow id=d36661e4253 href="http://www.ncbi.nlm.nih.gov/pubmed/23123547">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4256 href="http://dx.doi.org/10.1016/j.juro.2012.10.120">Publisher Full Text </a> | <a target=xrefwindow id=d36661e4260 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3926865">Free Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/10854965"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e4269 class=n-a></a>International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, <i>et al. </i>: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. <i>J Clin Oncol.</i> 2011; <b>29</b>(16): 2171–7. <a target=xrefwindow id=d36661e4280 href="http://www.ncbi.nlm.nih.gov/pubmed/21502557">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4283 href="http://dx.doi.org/10.1200/JCO.2010.32.3139">Publisher Full Text </a> | <a target=xrefwindow id=d36661e4287 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3107740">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/10854965">F1000 Recommendation</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d36661e4300 class=n-a></a>Culp SH, Dickstein RJ, Grossman HB, <i> et al.</i>: Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. <i>J Urol.</i> 2014; <b>191</b>(1): 40–7. <a target=xrefwindow id=d36661e4311 href="http://www.ncbi.nlm.nih.gov/pubmed/23911605">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4314 href="http://dx.doi.org/10.1016/j.juro.2013.07.061">Publisher Full Text </a> | <a target=xrefwindow id=d36661e4318 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4158919">Free Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733473354"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e4327 class=n-a></a>Moschini M, Soria F, Klatte T, <i> et al.</i>: Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. <i>Clin Genitourin Cancer.</i> 2017; <b>15</b>(2): e267–e273. <a target=xrefwindow id=d36661e4338 href="http://www.ncbi.nlm.nih.gov/pubmed/27530435">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4341 href="http://dx.doi.org/10.1016/j.clgc.2016.07.014">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733473354">F1000 Recommendation</a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725276476"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d36661e4354 class=n-a></a>Sternberg CN, Skoneczna I, Kerst JM, <i> et al.</i>: Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. <i>Lancet Oncol.</i> 2015; <b>16</b>(1): 76–86. <a target=xrefwindow id=d36661e4365 href="http://www.ncbi.nlm.nih.gov/pubmed/25498218">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4368 href="http://dx.doi.org/10.1016/S1470-2045(14)71160-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725276476">F1000 Recommendation</a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d36661e4381 class=n-a></a>Dong F, Shen Y, Gao F, <i> et al.</i>: Nomograms to Predict Individual Prognosis of Patients with Primary Small Cell Carcinoma of the Bladder. <i>J Cancer.</i> 2018; <b>9</b>(7): 1152–64. <a target=xrefwindow id=d36661e4392 href="http://www.ncbi.nlm.nih.gov/pubmed/29675096">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4395 href="http://dx.doi.org/10.7150/jca.23344">Publisher Full Text </a> | <a target=xrefwindow id=d36661e4399 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5907663">Free Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d36661e4409 class=n-a></a>Kouba EJ, Cheng L: Understanding the Genetic Landscape of Small Cell Carcinoma of the Urinary Bladder and Implications for Diagnosis, Prognosis, and Treatment: A Review. <i>JAMA Oncol.</i> 2017; <b>3</b>(11): 1570–8. <a target=xrefwindow id=d36661e4417 href="http://www.ncbi.nlm.nih.gov/pubmed/28334324">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4420 href="http://dx.doi.org/10.1001/jamaoncol.2016.7013">Publisher Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d36661e4429 class=n-a></a>Millis SZ, Bryant D, Basu G, <i> et al.</i>: Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. <i>Clin Genitourin Cancer.</i> 2015; <b>13</b>(1): e37–49. <a target=xrefwindow id=d36661e4440 href="http://www.ncbi.nlm.nih.gov/pubmed/25178641">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4443 href="http://dx.doi.org/10.1016/j.clgc.2014.07.010">Publisher Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d36661e4452 class=n-a></a>Zheng X, Liu D, Fallon JT, <i> et al.</i>: Distinct genetic alterations in small cell carcinoma from different anatomic sites. <i>Exp Hematol Oncol.</i> 2015; <b>4</b>: 2. <a target=xrefwindow id=d36661e4463 href="http://www.ncbi.nlm.nih.gov/pubmed/25937998">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4466 href="http://dx.doi.org/10.1186/2162-3619-4-2">Publisher Full Text </a> | <a target=xrefwindow id=d36661e4470 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4417281">Free Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d36661e4479 class=n-a></a>Siefker-Radtke AO, Kamat AM, Grossman HB, <i> et al.</i>: Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. <i>J Clin Oncol.</i> 2009; <b>27</b>(16): 2592–7. <a target=xrefwindow id=d36661e4490 href="http://www.ncbi.nlm.nih.gov/pubmed/19414678">PubMed Abstract </a> | <a target=xrefwindow id=d36661e4493 href="http://dx.doi.org/10.1200/JCO.2008.19.0256">Publisher Full Text </a> | <a target=xrefwindow id=d36661e4497 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4879720">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 25 Jul 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1137&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1137&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Suite 853, Houston, TX, 77030, USA<br/> <p> <div class=margin-bottom> Justin T. Matulay <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Ashish M. Kamat <br/> <span>Roles: </span> Conceptualization, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-1137/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 25 Jul 2018, 7:1137 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.14903.1">https://doi.org/10.12688/f1000research.14903.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Matulay JT and Kamat AM. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=16224 data-id=14903 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14903.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-1137/v1/pdf?article_uuid=f21eaa3f-9a22-415e-b3b6-84c7e4dff4fd" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.14903.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Matulay JT and Kamat AM. Advances in risk stratification of bladder cancer to guide personalized medicine [version 1; peer review: 4 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1137 (<a href="https://doi.org/10.12688/f1000research.14903.1" target=_blank>https://doi.org/10.12688/f1000research.14903.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=14903 id=mobile-track-article-signin-14903 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14903?target=/articles/7-1137"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16224 /> <input name=articleId type=hidden value=14903 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Rodolfo Montironi</strong>, School of Medicine, United Hospitals, Institute of Pathological Anatomy and Histopathology, Polytechnic University of the Marche Region (Ancona), Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Robert D Siemens</strong>, Department of Urology, Kingston General Hospital Research Institute, Canada </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Francisco X Real</strong>, Epithelial Carcinogenesis Group, Cancer Cell Biology Programme, Spanish National Cancer Research Centre, Spain </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Michael O Koch</strong>, Department of Urology, Indiana University, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 25 Jul 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1137&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1137&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=36731-36210></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=36733-36209></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=36734-36208></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=36732-36211></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=4><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> <th class="c-report-timeline__headings-version p-article__color--dark">4</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-1137/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>25 Jul 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Rodolfo Montironi</strong>, School of Medicine, United Hospitals, Institute of Pathological Anatomy and Histopathology, Polytechnic University of the Marche Region (Ancona), Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Robert D Siemens</strong>, Department of Urology, Kingston General Hospital Research Institute, Canada </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Francisco X Real</strong>, Epithelial Carcinogenesis Group, Cancer Cell Biology Programme, Spanish National Cancer Research Centre, Spain </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Michael O Koch</strong>, Department of Urology, Indiana University, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-1137&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-1137/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Advances in risk stratification of bladder...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-1137/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-1137/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-1137/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Matulay JT and Kamat AM');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-1137/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-1137",
            templates : {
                twitter : "Advances in risk stratification of bladder cancer to guide personalized.... Matulay JT and Kamat AM, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-1137/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Advances in risk stratification of bladder cancer to guide personalized medicine", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Advances in risk stratification of bladder cancer to guide personalized medicine", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/14903/16224")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "16224");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "36208": 0,
                           "36209": 0,
                           "36210": 0,
                           "36211": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "f94fd86b-246f-47bc-b3e2-2fb51b23d5e4";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1137.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1137.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1137.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-1137.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-1137.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>